




Vitamin D

4th Edition



Editor-in-Chief
David Feldman

Sr. Associate Editor
J. Wesley Pike

Associate Editors
Roger Bouillon
Edward Giovannucci
David Goltzman
Martin Hewison

Volume One | Biochemistry, Physiology and Diagnostics



VITAMIN D
VOLUME 1: BIOCHEMISTRY,
PHYSIOLOGY AND DIAGNOSTICS

This page intentionally left blank

VITAMIN D

VOLUME 1: BIOCHEMISTRY, PHYSIOLOGY AND DIAGNOSTICS

FOURTH EDITION

Editor-in-Chief

DAVID FELDMAN

Senior Associate Editor

J. WESLEY PIKE

Associate Editors

ROGER BOUILLON

EDWARD GIOVANNUCCI

DAVID GOLTZMAN

MARTIN HEWISON



ACADEMIC PRESS

An imprint of Elsevier

Academic Press is an imprint of Elsevier
125 London Wall, London EC2Y 5AS, United Kingdom
525 B Street, Suite 1800, San Diego, CA 92101-4495, United States
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom

Copyright © 2018 Elsevier Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

Library of Congress Cataloging-in-Publication Data

A catalog record for this book is available from the Library of Congress

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library

ISBN: 978-0-12-809965-0

For information on all Academic Press publications visit our website at <https://www.elsevier.com/books-and-journals>



Publisher: Mica Haley

Acquisition Editor: Tari Broderick

Editorial Project Manager: Lisa Eppich

Production Project Manager: Mohanambal Natarajan

Designer: Christian Bilbow

Typeset by TNQ Books and Journals

Contents

List of Contributors	xxiii	The Evolution of Skin Pigmentation in <i>Homo sapiens</i>	36
In Memoriam	xxix	The Effects of Cultural Buffering, Rapid Migrations, and Modern Lifestyles on Skin Color and Vitamin D	38
Preface to the Fourth Edition	xxxi	References	40
Abbreviations	xxxiii	Further Reading	44
Relevant Lab Values in Adults and Children	xxxvii		

VOLUME I

I

HISTORY, CHEMISTRY METABOLISM, CIRCULATION & REGULATION

1. Historical Overview of Vitamin D

HECTOR F. DELUCA

Discovery of the Vitamins	3
Discovery of the Physiological Functions of Vitamin D	5
Discovery of the Hormonal Form of Vitamin D	6
Acknowledgment	9
References	9

2. Evolutionary Biology: Mysteries of Vitamin D in Fish

DAVID R. FRASER

Biological Distribution of Vitamin D	14
Evolutionary Origins of Vitamin D	14
Evolution of Vitamin D Function	16
Origin of Vitamin D in Fish	16
Functional Metabolism of Vitamin D in Fish	19
A Possible Role for Sunlight in the Origin of Vitamin D in Fish	19
Vitamin D Function in Fish	21
Transport of Vitamin D and Its Metabolites	23
Vitamin D Toxicity From Oral Ingestion	23
References	24

3. Evolution of Human Skin Color and Vitamin D

NINA G. JABLONSKI

Introduction	30
The Solar Context of Human Skin Color Evolution	30
The Nature of the Selective Factors Leading to the Evolution of Skin Pigmentation in Early <i>Homo</i>	31
Folate Conservation and the Evolution of Permanent Protective Pigmentation	32
Early Hominin Dispersal Out of the Tropics and Vitamin D Production	32

4. Photobiology of Vitamin D

MICHAEL F. HOLICK

Introduction	45
Historical Perspective	45
Photobiology of Vitamin D	46
Role of Sunlight and Dietary Vitamin D in Bone Health, Overall Health, and Well-being	50
Sunlight, Vitamin D, and Skin Cancer	51
Conclusions	52
References	53
Further Reading	55

5. The Activating Enzymes of Vitamin D Metabolism (25- and 1 α -Hydroxylases)

GLENVILLE JONES, DAVID E. PROSSER AND MARTIN KAUFMANN

Introduction	57
General Information Regarding Vitamin D Hydroxylases	59
Vitamin D ₃ -25-Hydroxylases	59
25-Hydroxyvitamin D-1 α -hydroxylase	66
Additional Topics	70
References	74

6. CYP24A1: Structure, Function, and Physiological Role

RENÉ ST-ARNAUD AND GLENVILLE JONES

Introduction	81
CYP24A1-Catalyzed Pathways	82
C24-Oxidation Pathway	82
C23-Hydroxylation Pathway	83
CYP24A1, a Multifunctional Enzyme	83
Biological Relevance of the C24-Oxidation Pathway	84
Structure–Function Relationships	84
Mutations of CYP24A1 and Idiopathic Infantile Hypercalcemia	85
Preclinical Models of Idiopathic Infantile Hypercalcemia	87
Putative CYP24A1 Involvement in Other Systems	87
CYP24A1 in Chronic Kidney Disease	87
Role of 24,25(OH) ₂ D in Chondrocyte Maturation	88
24,25(OH) ₂ D and Fracture Repair	88
Perspectives	90
References	91

7. The Vitamin D-Binding Protein

ROGER BOUILLON AND STEVEN PAUWELS

Summary	97
Introduction	98
Vitamin D-Binding Protein: Gene and Protein Structure	99
Functions of Vitamin D-Binding Protein	102
The Vitamin D-Binding Protein–Actin Complex	107
Conclusions and Perspectives	109
References	110

8. Regulation of Renal and Extrarenal 1 α -Hydroxylase

DEAN P. LARNER, JOHN S. ADAMS AND MARTIN HEWISON

Introduction	117
Renal 1 α -Hydroxylase	118
Extrarenal Expression of 1 α -Hydroxylase	121
Conclusions and Future Prospects	129
References	130

II

MECHANISM OF ACTION

9. Genome-Wide Perspectives on Vitamin D Receptor–Mediated Control of Gene Expression in Target Cells

J. WESLEY PIKE, MARK B. MEYER, SEONG M. LEE, MELDA ONAL AND NANCY A. BENKUSKY

Introduction	142
The Biology of Vitamin D	142
The Metabolic Activation of Vitamin D	144
Overview of the Vitamin D Receptor: The Protein, Its Structure, and Function	146
Recent Advances in the Mechanisms of Action of Vitamin D	149
Advances in Understanding the Regulation of the Vitamin D Receptor Gene	159
Exploiting Humanized VDR Transgenic Mice to Understand Expression, Regulation, and VDR Protein Function In Vivo	163
Establishing a Humanized Mouse Model for the Study of Human Disease	165
Summary and Conclusions	167
Acknowledgments	167
References	167

10. Diverse Mechanisms of Transcriptional Regulation by the Vitamin D Receptor

JOHN H. WHITE, REYHANEH SALEHI-TABAR, VASSIL DIMITROV AND MANUELLA BOUTTIER

Introduction	175
Interplay Between Transforming Growth Factor β and Vitamin D Receptor Signaling	176
The Vitamin D Receptor and Transcription Factor Activator Protein-1	177
Interplay Between VDR and JAK/STAT Signaling in Immunity	177

Regulation of Wnt Signaling by the Vitamin D Receptor: A Molecular Basis for Cancer Prevention	177
Control of FoxO Protein Function by the Vitamin D Receptor	179
Regulation of the c-MYC/MXD1 Network by the Hormone-Bound Vitamin D Receptor	180
Multiple Mechanisms of Regulation of NF- κ B Signaling by the Hormone-Bound Vitamin D Receptor	182
Insights Into Transcriptional Regulation by the Vitamin D Receptor from Genomics Studies	183
Conclusions	183
References	183

11. Structural Basis for Ligand Activity in Vitamin D Receptor

ANNA Y. BELORUSOVA AND NATACHA ROCHEL

Introduction	189
1 α ,25-Dihydroxyvitamin D ₃ Recognition by Vitamin D Receptor	191
Natural Metabolites	193
Other Vitamin D Receptor Natural Ligands	194
Secosteroidal Analogs of 1 α ,25-Dihydroxyvitamin D ₃	195
Structures of Vitamin D Receptor With Analogs That Induce Structural Rearrangements	200
Synthetic Mimics of 1 α ,25-Dihydroxyvitamin D ₃	203
Conclusions and Perspectives	205
Acknowledgments	205
References	206

12. Ligand-Independent Actions of Vitamin D Receptor

GILLES LAVERNY AND DANIEL METZGER

The Vitamin D Receptor	211
Skeletal Defects Induced by Impaired Vitamin D Receptor Signaling	211
Ligand-Independent Role of Vitamin D Receptor in Hair Cycle	212
Unliganded Vitamin D Receptor Repressive Activities Induce Severe Skeletal Defects	212
Toward Improved Diagnosis and Treatments of Hereditary Vitamin D Resistant Rickets Patients	213
Conclusion and Perspectives	214
Acknowledgments	215
References	215

13. Vitamin D and Chromatin

CARSTEN CARLBERG

Introduction	217
The Nuclear Receptor Superfamily Member Vitamin D Receptor	218
Genome-Wide Location of Vitamin D Receptor-Binding Sites	219
CTCF as Organizer of Vitamin D-Dependent Chromatin Domains	220
The Impact of Epigenomics	220
Vitamin D-Triggered Epigenome Changes	221
A Chromatin Model of Vitamin D Signaling Emerges	222
Vitamin D Signaling In Vivo	222
Conclusion	223
Acknowledgments	224
References	224

14. Mesenchymal Differentiation, Epigenetic Dynamics, and Interactions With VDR		Major Regulatory Functions of Osteoblasts and Osteocytes and Control by the Vitamin D Endocrine System	297
MARK B. MEYER, NANCY A. BENKUSKY AND J. WESLEY PIKE		Effects of 1,25(OH) ₂ D ₃ on Osteoblast Differentiation	300
Genetic Control of Mesenchymal Lineage Cells	227	Regulation of Intracellular Signaling Pathways by 1,25(OH) ₂ D ₃	302
Epigenetic Fate Determination	231	Summary and Conclusions	303
Osteoblast Enhancer Complex: Consolidated and Dispersed Dynamics of Transdifferentiation	234	References	304
Conclusions	240		
Conflict of Interest	240		
References	240		
15. Vitamin D and MicroRNAs		18. Osteoclastogenesis and Vitamin D	
HENGGUANG ZHAO, SRI RAMULU N. PULLAGURA, SANDRA RIEGER AND THOMAS S. LISSE		YUKO NAKAMICHI, NAOYUKI TAKAHASHI, NOBUYUKI UDAGAWA AND TATSUO SUDA	
Introduction	245	Introduction	309
MicroRNAs: The Posttranscriptional Age	247	Regulation of Mineral Metabolism by Vitamin D, Parathyroid Hormone, and Fibroblast Growth Factor 23	310
Complexity of MicroRNA Regulation, Biogenesis, and Posttranscriptional Regulatory Actions	247	Phenotypes of Vitamin D Receptor Knockout Mice	311
Nuclear Receptors and MicroRNAs	250	Regulation of Osteoclastogenesis by the Receptor Activator of Nuclear Factor- κ B Ligand/Receptor Activator of Nuclear Factor- κ B/Osteoprotegerin System	312
Duality Among MicroRNAs and the Vitamin D Synthesis, Metabolism, and Signaling Systems	250	In Vitro Regulation of Osteoclastogenesis by Vitamin D	312
Interplay Between Vitamin D and MicroRNAs in Biological Systems	255	In Vivo Regulation of Osteoclastogenesis by Vitamin D Compounds	313
Strategies for MicroRNA and Target Identification for Vitamin D Research	260	Conclusion	315
Concluding Remarks	261	References	316
Acknowledgments	262		
References	262	19. Vitamin D Activities in Osteocytes	
16. Vitamin D Sterol/Vitamin D Receptor Conformational Dynamics and Nongenomic Actions		PAUL H. ANDERSON, GERALD J. ATKINS, HOWARD A. MORRIS AND DAVID M. FINDLAY	
MATHEW T. MIZWICKI AND ANTHONY W. NORMAN		Introduction	319
Introduction	269	Cell Biology of Osteocytes	320
1 α ,25(OH) ₂ Vitamin D ₃ Regulation of Genomic Versus Nongenomic Signaling	270	Direct Actions of 1,25-Dihydroxyvitamin D on Osteocyte Maturation and Activities	321
Vitamin D ₃ Sterol Chemistry	271	Receptor Activator of Nuclear Factor κ B Ligand	321
1,25(OH) ₂ D ₃ -Mediated Rapid, Nongenomic Responses	275	Vitamin D Metabolism Within Osteocytes	323
The Plasma Membrane Vitamin D Receptor	280	The Role of Osteocytes and Vitamin D in Bone Turnover	323
The Vitamin D Receptor Conformational Ensemble Model	281	The Role of Vitamin D and Osteocytes in Endocrine Feedback	324
Vitamin D Receptor Ligand Specificity: Does an Unliganded Vitamin D Receptor Ever Exist In Vivo?	286	Conclusions	324
References	287	References	325
		20. Regulation of Intestinal Calcium and Phosphate Absorption	
		JAMES C. FLEET	
		An Overview of Intestinal Calcium Absorption	329
		An Overview of Intestinal Phosphate Absorption	336
		References	338
		21. Calbindin-D_{28K} and Calbindin-D_{9K} and the Epithelial Calcium Channels TRPV5 and TRPV6	
		SYLVIA CHRISTAKOS, LEILA J. MADY AND PUNEET DHAWAN	
		Introduction and General Considerations, the Calbindins	343
		Localization and Proposed Functional Significance of the Calbindins	345
		Regulation of Calbindin Gene Expression	349
		Epithelial Calcium Channels	351
		Conclusion	353
		References	354

III

MINERAL AND BONE HOMEOSTASIS

17. Vitamin D Regulation of Osteoblast Function

JEROEN VAN DE PEPEL, RENNY T. FRANCESCHI, YAN LI AND BRAM C.J. VAN DER EERDEN

Introduction	295
Properties of Mature Osteoblasts and Osteocytes	295

22. Calcium Homeostasis and Eggshell Biom mineralization in Female Chicken		Effects of Vitamin D, 25(OH)D ₃ and 1 α ,25(OH) ₂ D ₃ on the Renal Handling of Calcium and Phosphorus	441
YVES NYS AND NATHALIE LE ROY		Distribution and Regulation of Vitamin D-Dependent Proteins in the Kidney	442
Introduction	361	Conclusion	450
Mineralization Associated With Laying Hen Reproduction	362	References	450
Transepithelial Transfer of Calcium	364		
Regulation of Calcium Metabolism in Hens	369	27. Vitamin D and the Parathyroids	
Acknowledgments	378	JUSTIN SILVER AND TALLY NAVEH-MANY	
References	378	Introduction	461
		Parathyroid Hormone Biosynthesis	462
23. Mineralization in Mammals		The Parathyroid Hormone Gene	462
ADELE L. BOSKEY		Development of the Parathyroid and Tissue-Specific Expression of the Parathyroid Hormone Gene	463
Introduction	383	Regulation of Parathyroid Hormone Gene Expression	463
Direct and Indirect Effects of Vitamin D and Vitamin D Metabolites on Mineralization	384	Summary	470
Methods for Quantifying Tissue Mineralization	387	References	471
Mechanism of Effects of Vitamin D on Mineralization	391		
Mineralization and Mineral Properties in Systems With Vitamin D Alterations	394	28. The Calcium-Sensing Receptor and Vitamin D	
Conclusions	397	GEOFFREY N. HENDY	
Acknowledgments	398	Introduction	477
References	398	The Calcium-Sensing Receptor	478
Further Reading	403	Overview of Extracellular Ca ²⁺ Homeostasis: Roles of Calcium-Sensing Receptor and Vitamin D Receptor	481
24. Cartilage		Calcium-Sensing Receptor and Vitamin D Receptor in Tissues Involved in Ca ²⁺ Homeostasis	482
BARBARA D. BOYAN, MARYAM DOROUDI, KAYLA SCOTT AND ZVI SCHWARTZ		Calcium-Sensing Receptor and Vitamin D Receptor in Tissues Uninvolved in Extracellular Ca ²⁺ Homeostasis	489
Properties of Cartilage Tissues	405	Mouse Models of Calcium-Sensing Receptor Deletion Relative to Presentation in Humans	490
Regulation by Vitamin D	406	Conclusions	490
Rapid Actions of Vitamin D and Nongenomic Mechanisms	410	References	490
Summary	414		
References	414	29. Vitamin D in Dentoalveolar and Oral Health	
		BRIAN L. FOSTER AND PHILIPPE P. HUJOEL	
25. Vitamin D and Bone: An Integrated Approach		Introduction	497
GEERT CARMELIET		A Brief Primer on Dentoalveolar Cells and Tissues	498
Link Between Bone Metabolism, Calcium Homeostasis, and 1,25(OH) ₂ D ₃ Activity	419	Vitamin D Metabolism and Mechanisms of Action on Dental Cells	501
1,25(OH) ₂ D ₃ and Bone Metabolism During a Positive Calcium Balance	420	Vitamin D, Rickets, and the Oral Tissues	503
Negative Calcium Balance Resulting From Insufficient Vitamin D Action	424	Hereditary Vitamin D-Related Diseases and Dentoalveolar Tissues	506
Negative Calcium Balance With Sufficient Vitamin D	426	Vitamin D and Oral Health	511
Vitamin D and Fibroblast Growth Factor 23	428	Conclusions	513
Conclusion	429	Acknowledgments	513
References	430	References	513
		30. The Role of Vitamin D and Its Receptor in Hair Follicle Biology	
		MARIE B. DEMAY	
		Introduction	521
		Hair Cycle	521
		Keratinocyte Stem Cells	523
		Pathways Important for Keratinocyte Stem Cell Function	523

IV

EXTRA-SKELETAL TARGETS

26. Vitamin D and the Kidney			
PETER J. TEBBEN AND RAJIV KUMAR			
Introduction	437		
Role of the Kidney in the Metabolism of 25-Hydroxyvitamin D	439		

The Vitamin D Receptor Suppresses PPAR γ Signaling in Keratinocyte Stem Cells	524	Translational Considerations	592
Conclusions	524	Conclusions and Future Directions	593
References	525	References	593
31. Vitamin D, Calcium, and the Epidermis		35. Vitamin D and Skeletal Muscle	
DANIEL D. BIKLE		CHRISTIAN M. GIRGIS	
Introduction	527	Skeletal Muscle Physiology	597
Cutaneous Production of Vitamin D and Its Biologically Active Metabolites	528	Vitamin D Receptor in Muscle	598
Regulation of Keratinocyte Differentiation	529	Vitamin D and Calcium Signaling in Muscle	601
Role of Vitamin D Signaling in Skin Cancer	537	Vitamin D and Phosphate Signaling in Muscle	602
Role of Vitamin D Signaling in Epidermal Wound Repair	538	Vitamin D and Insulin Signaling in Muscle	602
References	539	Vitamin D, Muscle Contraction, and Strength	603
		Vitamin D, Muscle Development, and Mass	604
		Vitamin D, Muscle Injury, and Repair	606
		Vitamin D and Age-Related Changes in Muscle	606
		Vitamin D and Bone Muscle Cross-Talk	607
		Conclusions and Future Directions	607
		References	609
32. Vitamin D and the Cardiovascular System		36. Understanding Vitamin D From Mouse Knockout Models	
AMY E. RIEK, RITHWICK RAJAGOPAL AND CARLOS BERNAL-MIZRACHI		DAVID GOLTZMAN, GEOFFREY N. HENDY, ANDREW C. KARAPLIS, RICHARD KREMER AND DENSHUN MIAO	
Introduction	545	Vitamin D Metabolism	614
Vascular Physiology	546	1,25 Dihydroxyvitamin D/Vitamin D Receptor System and Mineral and Skeletal Homeostasis	614
Identification of the Vitamin D Receptor in the Vascular System	546	Extraskeletal Actions of 1,25 dihydroxyvitamin D	619
Vascular Relaxation	547	Conclusion	625
Structural Vascular Changes	548	References	625
Vascular Inflammation	549	Further Reading	631
Angiogenesis	551		
Blood Coagulation and Fibrinolysis	552		
Animal Models	552		
Clinical Studies in Cardiovascular Disease	555		
Conclusion	556		
Acknowledgments	556		
References	557		
33. Vitamin D Brain Development and Function		V	
DARRYL EYLES AND JOHN J. MCGRATH		HUMAN PHYSIOLOGY	
Introduction	564		
Vitamin D Signaling in the Brain	564	37. Pharmacology and Pharmacokinetics	
Dietary Vitamin D Deficiency, Effect on Brain Development and Function	567	INEZ SCHOENMAKERS AND KERRY S. JONES	
The Effects of Excess Vitamin D on Brain Development and Function	571	Overview	636
Vitamin D Regulates Essential Processes in Normal Brain Development	572	Vitamin D Absorption	636
Possible Neuroprotective Mechanisms of Vitamin D in the Developing Brain	573	Kinetics of Cutaneous Synthesis	638
Developmental Vitamin D Deficiency and Neuropsychiatric Disorders	574	Tissue Distribution	639
Conclusions	575	Metabolism and Determinants of Metabolic Fate of Vitamin D	641
References	576	Half-Lives of Vitamin D Metabolites	642
		Factors Influencing Vitamin D Half-Life	644
		The Pharmacokinetics of Bound and Free Vitamin D Metabolites	646
		Influence of Vitamin D-Binding Protein Genotype and Concentration on Vitamin D Metabolism and 25(OH)D Half-Life	647
		Dose-Response to Vitamin D Supplementation	648
		The 3-Epimer of 25(OH)D and 1,25(OH) $_2$ D	652
		Catabolism and Excretion	652
		Vitamin D Toxicity	653
		Acknowledgments	653
		References	653
34. Vitamin D, Vitamin D Receptor, and Adipose Tissue: Focus on Cellular Mechanisms			
CARMEN J. NARVAEZ, DONALD G. MATTHEWS AND JOELLEN WELSH			
Adipose Tissue: Storage Depot and Target for Vitamin D	583		
Effect of Vitamin D on Adipogenesis at the Cellular Level	585		
Impact of Vitamin D Signaling on Adiposity in Mouse Models	590		

38. Vitamin D Role in the Calcium and Phosphorus Economies

ROBERT P. HEANEY AND LAURA A. GRAEFF-ARMAS

Introduction	663
Overview of the Calcium Economy	663
Overview of the Phosphorus Economy	668
Calcium and Phosphorus Absorptive Inputs	669
Physiological Sources of Vitamin D Activity	674
Optimal Vitamin D Status	675
Summary and Conclusions	676
References	676

39. Fetus, Neonate, and Infant

CHRISTOPHER S. KOVACS

Overview of Calcium Metabolism in the Fetus	679
Animal Data Relevant to Vitamin D and the Fetus	681
Human Data Relevant to Vitamin D and the Fetus	684
Overview of Calcium Metabolism in the Neonate and Infant	690
Animal Data Relevant to Vitamin D and the Neonate and Infant	692
Human Data Relevant to Vitamin D and the Neonate and Infant	693
Conclusions	698
References	699

40. Consequences of Perinatal Vitamin D Deficiency on Later Bone Health

CYRUS COOPER, ELIZABETH M. CURTIS, REBECCA J. MOON, ELAINE M. DENNISON AND NICHOLAS C. HARVEY

Introduction	709
Vitamin D Physiology and Epidemiology in Pregnancy	709
The Lifecourse Determinants of Osteoporosis	710
Maternal Vitamin D Supplementation During Pregnancy and Offspring Bone Health	717
Maternal Vitamin D Supplementation During Pregnancy and Offspring Bone Health: The MAVIDOS Trial	721
Conclusion	724
Acknowledgment	725
References	725

41. Adolescence and Acquisition of Peak Bone Mass

RICHARD LEWIS, EMMA LAING AND CONNIE WEAVER

Introduction	731
Pubertal Bone Acquisition	732
Sex and Race Differences	734
Serum 25(OH)D in Children and Adolescents	736
Vitamin D and Intermediate Endpoints of Vitamin D and Bone Metabolism	740
Vitamin D and Other Predictors of Calcium Retention	743
Vitamin D and Bone	743
Vitamin D and Muscle	747
Vitamin D Requirements in Children and Adolescents	747
Summary and Conclusions	748
References	748

42. Pregnancy, Lactation, and Postweaning Recovery

CHRISTOPHER S. KOVACS

Introduction	755
Overview of Mineral Physiology During Pregnancy	755
Animal Data Relevant to Vitamin D and Pregnancy	759
Human Data Relevant to Vitamin D and Pregnancy	761
Overview of Mineral Physiology During Lactation and Postweaning Recovery	763
Animal Data Relevant to Vitamin D, Lactation, and Postweaning Recovery	770
Human Data Relevant to Vitamin D, Lactation, and Postweaning Recovery	771
Conclusions	773
References	773

43. Role in Reproductive Biology and Reproductive Dysfunction in Women

LUBNA PAL AND HUGH S. TAYLOR

Introduction	783
Procreative Relevance of Vitamin D—Animal Models	784
Therapeutic Relevance of Vitamin D—Data From Experimental Animal Models of Human Gynecological Disorders	784
Vitamin D—Relevance in Human Female Reproductive Physiology	785
Vitamin D—Relevance in Female Reproductive Disorders	785
Polycystic Ovary Syndrome	785
Premenstrual Syndrome	787
Menstrual Pain (Dysmenorrhea)	788
Endometriosis	788
Uterine Leiomyomas (Fibroids)	789
Vitamin D and Female Infertility	789
Concluding Remarks	792
References	792

44. Vitamin D, Reproductive Biology, and Dysfunction in Men

IDA M. BOISEN, LASSE BØLLEHUUS HANSEN, LI J. MORTENSEN AND MARTIN BLOMBERG JENSEN

Introduction	797
Vitamin D and Leydig Cell Function	800
Vitamin D and Sex Steroids	803
Vitamin D and Sertoli Cell Function	805
Vitamin D and Germ Cell Function	806
VDR, Activation and Inactivation of Vitamin D in Human Sperm	807
Vitamin D and Sperm Function	808
Vitamin D, Epididymis, Prostate, and Seminal Vesicle	811
Vitamin D and Reproductive Hormones	812
Vitamin D, Semen Quality, and Fertility: Functional Models	813
Vitamin D, Semen Quality, and Fertility: Human Studies	816
Testicular Germ Cell Tumors	818
Concluding Remarks and Future Perspectives	819
References	820

45. Vitamin D and the Renin-Angiotensin System

YAN CHUN LI

Introduction	825
The Renin-Angiotensin System	826
Vitamin D Regulation of the Renin-Angiotensin System	829
Vitamin D and the Renin-Angiotensin System in Disease	833
Conclusion	840
References	840

46. Parathyroid Hormone, Parathyroid Hormone-Related Protein, and Calcitonin

JOHN J. WYSOLMERSKI

Parathyroid Hormone	849
Parathyroid Hormone-Related Protein	856
Calcitonin	861
References	864

47. FGF23 Counter-Regulatory Hormone for Vitamin D Actions on Mineral Metabolism, Hemodynamics, and Innate Immunity

L. DARRYL QUARLES

Introduction	871
Parathyroid Hormone-Vitamin D Axis: Key Regulator of Calcium Homeostasis	872
Fibroblast Growth Factor-23/ α -Klotho	872
Fibroblast Growth Factor-23 Endocrine Networks	873
Noncanonical α -Klotho and Fibroblast Growth Factor-23 Signaling	876
Conclusions	879
References	879

VI

DIAGNOSIS AND MANAGEMENT

48. Approach to the Patient With Metabolic Bone Disease

MICHAEL P. WHYTE

Introduction	887
Diagnostic Evaluation	888
Biochemical Investigation	897
Histopathological Assessment	898
Treatment	900
Conclusions	901
Acknowledgments	902
References	902

49. Detection of 1,25-Dihydroxyvitamin D in Human Serum Using Receptor Assisted Chemiluminescent Hormone Assay Technology

FABRIZIO BONELLI AND BRUCE W. HOLLIS

Introduction	903
Methodology	904

Identification of the DNA Consensus Sequence of the Immunoglobulin G VH and VL Gene, Expressed by Hybridoma Clone 11B4	905
Preparation of the Assay Reagents	905
Assay Format and Performance	905
Discussion	906
References	907

50. Mass Spectrometry Assays of Vitamin D Metabolites

MARTIN KAUFMANN, LUSIA SEPIASHVILI AND RAVINDER J. SINGH

Introduction	909
Approaches and Utility of Vitamin D Metabolite Measurements in the Clinical Laboratory Setting	910
Overview of Methodology for Analysis of Circulating Vitamin D Metabolites by LC-MS/MS	912
Application of LC-MS/MS to the Study of Vitamin D Metabolism in Animal Models	917
Future Directions	920
References	920

51. Free Vitamin D: Concepts, Assays, Outcomes, and Prospects

RENE F. CHUN AND CARRIE M. NIELSON

Introduction	925
Metabolism	926
Transportation and Internalization: Free Hormone Hypothesis and Bioavailable Ligand	926
Vitamin D-Binding Protein Genotype	928
Free Vitamin D: Mathematical Estimation	928
Free Vitamin D: Direct Physical Measurement	929
Potential Utility of Free 25(OH)D for Clinical- and Population-Based Detection of Vitamin D Deficiency	930
Conclusions and Knowledge Gaps	933
References	933

52. 25-Hydroxyvitamin D Assays: Standardization Guidelines, Problems, and Interpretation

CHRISTOPHER T. SEMPOS, GRAHAM D. CARTER AND NEIL C. BINKLEY

Introduction	939
Vitamin D Standardization Program Objectives	940
Standardization and Traceability	941
Vitamin D Standardization Program Standardization Protocols	942
Performance Testing/Quality Assessment of Assays for Vitamin D Metabolites	950
Vitamin D Standardization Program Efforts Going Into the Future	955
Summary and Conclusions	955
References	956

53. Bone Histomorphometry

JULIET COMPSTON, LINDA SKINGLE AND DAVID W. DEMPSTER

Introduction	960
Bone Biopsy	960

Histomorphometry	961	57A. The IOM–Endocrine Society Controversy	
Assessment of Mineralization	963	on Recommended Vitamin D Targets:	
Histological Diagnosis of Osteomalacia	964	In Support of the IOM Position	
Assessment of Bone Turnover	966	ROGER BOUILLON AND CLIFF ROSEN	
Assessment of Remodeling Balance	967	Introduction	1065
Assessment of Bone Structure	969	Vitamin D Status and Bone Health in Adults and the Elderly	1067
Influence of Vitamin D Status on Bone Histomorphometry	969	Vitamin D and Extraskelatal Health	1072
Future Developments	970	Lessons From Recently Updated Guidelines on Vitamin D	
References	971	Supplementation	1079
		Vitamin D and Human Health: What is the Optimal	
		Vitamin D Status	1079
		Summary of Recommendations	1081
		Highlights	1082
		References	1082
		57B. The IOM—Endocrine Society Controversy on	
		Recommended Vitamin D Targets: In Support	
		of the Endocrine Society Position	
		REINHOLD VIETH AND MICHAEL F. HOLICK	
		Section I. Defining the Disagreement Between IOM	
		and Endocrine Society	1092
		Section II. Scientific Basis for Why IOM Versus Endocrine	
		Society Values Differ in Terms of Bone Health	1094
		Section III. Toxicity and Perceptions of Risk of Higher	
		Vitamin D Intakes: Higher-Dose Clinical Trials	
		and Epidemiology U-Shaped Risk Findings	1098
		Section IV. Extraskelatal Effects of Vitamin D	1101
		Section V. Extraskelatal Effects: Cross-Sectional Observations	
		Versus the Findings of Double-Blind, Randomized	
		Clinical Trials	1101
		Section VI. Emerging Benefits of Higher Vitamin D:	
		Life Expectancy	1103
		Section VII. New Evidence That Vitamin D Lowers	
		Risk of Preterm Birth	1103
		Section VIII. Conclusion	1104
		References	1105
		Index for Volume 1	1109
54. Radiology of Rickets and Osteomalacia			
JUDITH E. ADAMS			
Introduction and Historical Aspects	975		
Vitamin D Deficiency	976		
Renal Osteodystrophy	981		
Renal Tubular Defects and Hypophosphatemia	987		
Differential Diagnoses	993		
Vitamin D Intoxication	997		
Conclusions	1001		
References	1001		
55. High-Resolution Imaging Techniques for			
Bone Quality Assessment			
ANDREW J. BURGHARDT, ROLAND KRUG AND SHARMILA MAJUMDAR			
Introduction	1007		
X-ray Computed Tomography	1008		
Magnetic Resonance Imaging	1021		
References	1031		
56. The Role of Vitamin D in Orthopedic Surgery			
AASIS UNNANUNTANA, ALEKSEY DVORZHINSKIY, BRIAN J. REBOLLEDO,			
SHEVAUN M. DOYLE, PANAGIOTA ANDREOPOULOU AND JOSEPH M. LANE			
Introduction	1043		
Impact on Orthopedic Trauma	1044		
Impact on Pediatric Orthopedics	1048		
Impact on Total Joint Arthroplasty	1050		
References	1054		
Introduction to Chapters 57A and 57B			
References	1063		

VOLUME II

VII

**POPULATION STUDIES: VITAMIN D
DEFICIENCY, NUTRITION,
SUNLIGHT, GENES & TRIALS**

**58. Methods of Evaluating Population Studies of
Vitamin D: Strengths and Weaknesses**

EDWARD GIOVANNUCCI

Introduction	3
Methods of Assessing Vitamin D Status	4
Main Challenges in the Epidemiologic Study of Vitamin D and Disease	7
Summary of Study Designs of Vitamin D	9
Conclusions	12
References	13

59. Worldwide Vitamin D Status

NATASJA VAN SCHOOR AND PAUL LIPS

Introduction	15
Vitamin D Status in North America (Including Canada and Mexico)	16
Vitamin D Status in South America	21
Vitamin D Status in Europe	21
Vitamin D Status in Middle East	21
Vitamin D Status in Asia	21
Vitamin D Status in Africa	21
Vitamin D Status in Oceania	26
Multicenter and Global Studies Using a Central Laboratory Facility	26
Ethnicity/Migration	34
Nutrition	34
Risk Groups	34
Implications	34
Conclusions	35
References	35

**60. Vitamin D in Foods: An Evolution of
Knowledge**

JANET M. ROSELAND, KATHERINE M. PHILLIPS, KRISTINE Y. PATTERSON,
PAMELA R. PEHRSSON AND CHRISTINE L. TAYLOR

Introduction	41
Challenges in Assessing the Vitamin D Content of Foods	42
Methods of Analysis for Vitamin D in Foods	47
Food Composition Data	54
Implications and Future Directions	61
Appendix A	62
References	74

**61. Determinants of Vitamin D Deficiency From Sun
Exposure: A Global Perspective**

WILLIAM B. GRANT, HARJIT P. BHATTOA AND PAWEL PLUDOWSKI

Background	79
Factors Affecting 25-Hydroxyvitamin D Concentrations	80
Predicting Vitamin D Deficiency	86
Conclusion	86
References	86

**62. Vitamin D Fortification and Supplementation
Policies to Correct Vitamin D Insufficiency/
Deficiency Globally**

SUSAN J. WHITING AND MONA S. CALVO

Introduction	91
Recommendations for Vitamin D Status	94
Strategies to Improve Nutrient Intakes	99
Public Health Measures for Reducing D Deficiency	104
Summary	106
References	106

63. Vitamin D and Food Fortification

KEVIN D. CASHMAN AND MAIREAD KIELY

Introduction	109
Current Intakes of Vitamin D in Young and Adult Populations in North America and Europe and How These Compare Against Dietary Targets?	112
Dietary Strategies for Increasing Vitamin D Intake: Bridging the Gap By Food Fortification	112
Consideration of Other Vitamin D-Fortified Foods	120
Vitamin D-Biofortified Foods	121
Safety Considerations and Prerequisite Data Required Prior to Initiating Public Health Measures	123
Concluding Remarks	124
References	125

64. Bariatric Surgery, Vitamin D, and Bone Loss

TIFFANY Y. KIM AND ANNE L. SCHAFFER

Introduction	129
Skeletal Effects of Bariatric Surgery	131
Potential Mechanisms of Bone Loss	134
Prevention and Treatment of Skeletal Effects	143
Acknowledgments	145
References	145

65. Genetics of the Vitamin D Endocrine System

ANDRÉ G. UITTERLINDEN

Introduction	151
Genetic Studies	153
Genome-Wide Association Studies	157
Future Developments	162
Acknowledgments	162
References	162

66. Randomized Clinical Trials of Vitamin D for the Primary Prevention of Cancer and Cardiovascular Disease With a Focus on the VITamin D and OmegA-3 Trial (VITAL)

SHARI S. BASSUK AND JOANN E. MANSON

Introduction	167
Vitamin D and Omega-3 Trial Study Design	168
Baseline Characteristics of VITAL Participants	170
Other Ongoing and Recently Completed Large and Midsized Trials of Vitamin D	173
Conclusion	174
Acknowledgments	174
References	175

VIII

DISORDERS

67. Vitamin D Deficiency and Nutritional Rickets in Children

JOHN M. PETTIFOR, KEBASHNI THANDRAYEN AND THOMAS D. THACHER

Introduction	179
Historical Perspective	179
The Epidemiology of Vitamin D Deficiency and Nutritional Rickets	180
Clinical Presentation	182
Biochemical Abnormalities	184
Radiologic Changes	185
The Growth Plate in Rickets	186
Treatment and Prevention	187
Dietary Calcium Deficiency	190
The Pathogenetic Spectrum of Nutritional Rickets	192
Conclusions	193
References	194

68. Vitamin D and Osteoporosis

PETER R. EBELING AND JOHN A. EISMAN

Effects of Vitamin D on the Skeleton	204
The Role of Vitamin D Genetic Factors in Osteoporosis and Possible Interactions With Vitamin D Therapy	205
Determining Optimal Serum 25 Hydroxyvitamin D Concentrations for Musculoskeletal Health	207
Effects of Vitamin D Alone or Calcium and Vitamin D on Bone Mineral Density	207
Primary Fracture Prevention With Vitamin D or Calcium and Vitamin D	209
Effect of Vitamin D Alone on Fractures	209
Single High Annual or Monthly Doses of Vitamin D	210
Primary Fracture Prevention With Calcium and Vitamin D	211
Metaanalyses	212
Safety	213
Secondary Fracture Prevention With Vitamin D or Calcium and Vitamin D	214
Effects of Active Vitamin D Analogs on Fractures	215

The Anabolic Vitamin D Analogs, 2MD	215
The Vitamin D Analogs, Eldecalcitol	215
Ongoing Large Randomized Controlled Trials of Vitamin D Supplementation	216
Future Directions for Vitamin D in Osteoporosis	216
References	216

69. Adult Vitamin D Deficiency: Fracture and Fall Prevention

BESS DAWSON-HUGHES AND HEIKE A. BISCHOFF-FERRARI

Vitamin D: Muscle and Balance	221
Vitamin D and Falls	222
Vitamin D: Bone Mineral Density and Fracture Risk	224
Trials Testing Higher Doses of Vitamin D Given at Infrequent Intervals	225
Conclusions	226
References	226

70. Clinical Disorders of Phosphate Homeostasis

EVA S. LIU AND HARALD JÜPPNER

Phosphate Homeostasis	229
Regulation of Phosphate Homeostasis	230
Phosphate and Vitamin D Metabolism	231
Clinical Symptoms of Hypophosphatemia and Hyperphosphatemia	231
Disorders of Phosphate Homeostasis	232
Genetic Hypophosphatemic Disorders With Low Fibroblast Growth Factor 23 Levels	239
Acquired Hypophosphatemic Disorders With Elevated Fibroblast Growth Factor 23 Levels	239
Genetic Hyperphosphatemic Disorders	240
Disorders of Altered Phosphate Load	240
References	241

71. Vitamin D Hydroxylation–Deficient Rickets, Type 1A: CYP27B1 Mutations

FRANCIS H. GLORIEUX AND RENÉ ST-ARNAUD

Introduction	249
Clinical Manifestations	250
Biochemical Findings	251
Genetic and Molecular Studies	252
Treatment of VDDR1A	255
Evolution of VDDR1A Under Treatment From Childhood to Adulthood	255
Perspective and Conclusions	258
References	260

72. Hereditary 1,25-Dihydroxyvitamin D Resistant Rickets

PETER J. MALLOY, DOV TIOSANO AND DAVID FELDMAN

Introduction	264
The Clinical Features of HVDRR	264
Mechanism of 1,25(OH) ₂ D Action	270
Cellular Basis of HVDRR	272

Molecular Basis for HVDRR	278		
Therapy of HVDRR	289		
Alopecia	292		
Concluding Remarks	293		
References	294		
73. The Role of Genetic Variation in CYP2R1, the Principal Vitamin D 25-Hydroxylase, in Vitamin D Homeostasis			
JEFFREY D. ROIZEN AND MICHAEL A. LEVINE			
Background	303		
CYP2R1 Is the Principal Human Vitamin D 25-Hydroxylase	304		
CYP2R1 and Vitamin D-Dependent Rickets	307		
In Vitro and In Silico Analyses of CYP2R1 Function	310		
Associations Between CYP2R1 Variants and Disease	312		
Conclusion and Future Directions	313		
References	313		
74. Infantile Hypercalcemia and CYP24A1 Mutations			
KARL P. SCHLINGMANN AND MARTIN KONRAD			
Infantile Hypercalcemia—Differential Diagnosis	317		
Idiopathic Infantile Hypercalcemia—Historical Aspects	319		
Spectrum of Disease Caused By CYP24A1 Mutations	320		
Mutations In CYP24A1—Molecular Genetics	323		
Functional Studies of Mutant CYP24A1	324		
Measurement of CYP24A1 Activity In Vivo	324		
CYP24A1 Mouse Model	325		
Additional Defects Leading to an Increased Action of Vitamin D	325		
Therapeutic Aspects	326		
Summary and Conclusions	327		
References	328		
75. Drug and Hormone Effects on Vitamin D Metabolism			
GREGORY R. EMKEY AND SOL EPSTEIN			
Introduction	331		
Hormone Effects on Vitamin D Metabolism	333		
Drug Effects on Vitamin D Metabolism	342		
Conclusion	354		
References	354		
76. Vitamin D and Organ Transplantation			
JESSICA M. FURST, EMILY M. STEIN, JESSICA STARR AND ELIZABETH SHANE			
Introduction	375		
Effects of Vitamin D on Immunity and Graft Rejection	375		
Vitamin D Deficiency Prior to Organ Transplant	376		
Vitamin D Deficiency Following Organ Transplant	377		
Treatment of Posttransplant Bone Loss With Vitamin D and Analogs	378		
Conclusions	381		
References	381		
Further Reading	373		
77. The Role of Vitamin D in Type 2 Diabetes and Hypertension			
EDITH ANGELLOTTI AND ANASTASSIOS G. PITTAS			
Epidemiology and Burden of Type 2 Diabetes and Hypertension	388		
Biologic Plausibility of an Association Between Vitamin D and Type 2 Diabetes and Hypertension	388		
Evidence From Human Studies for a Link Between Vitamin D and Type 2 Diabetes	391		
Evidence From Human Studies for a Link Between Vitamin D and Hypertension	406		
Summary of Evidence From Human Studies on Type 2 Diabetes and Hypertension and Limitations in the Study of Vitamin D	410		
Optimal Intake of Vitamin D in Relation to Type 2 Diabetes and Hypertension	414		
Conclusions	415		
References	415		
78. Vitamin D, Obesity, and the Metabolic Syndrome			
ELINA HYPPOÖNEN AND BARBARA J. BOUCHER			
Introduction	425		
Adipose Tissue as a Vitamin D Reserve	426		
Obesity and Vitamin D Deficiency	426		
Obesity, Vitamin D-Binding Proteins, and “Free” Vitamin D Concentrations	428		
The Effect of Weight Loss on Serum 25(OH)D Concentrations	429		
Can Vitamin D Supplementation Prevent, or Reduce, Obesity?	430		
Obesity and the Efficacy of Vitamin D Supplementation	431		
Brown Adipose Tissue, Obesity, and Vitamin D	433		
Obesity, Vitamin D, and Metabolic Syndrome	433		
Importance of Early Life D Status for Obesity and Subsequent Risks of Metabolic Syndrome, Type 2 Diabetes Mellitus, and Cardiovascular Disease	437		
Conclusions and Future Directions	439		
References	439		
79. Vitamin D and Renal Disease			
ADRIANA S. DUSSO AND JORGE B. CANNATA-ANDIA			
Introduction	445		
Renal Maintenance of the Vitamin D Endocrine System	448		
Critical Calcitriol/VDR Actions to Improve Parathyroid, Skeletal, Renal, and Cardiovascular Outcomes in CKD	456		
Acknowledgments	463		
References	463		
80. Calcitriol and Analogs in the Treatment of Chronic Kidney Disease			
ISHIR BHAN AND RAVI THADHANI			
Introduction	471		
Analogs of Vitamin D Used in Chronic Kidney Disease	472		
Analogs in Animal Models of Uremia	472		
Chronic Kidney Disease Stages 3–4	475		

End-Stage Renal Disease	477	The FGF23/Klotho/Vitamin D Axis, Nephrocalcinosis, and Cardiovascular Calcification	558
Cardiovascular Disease in Chronic Kidney Disease and Different Forms of Vitamin D	480	Vitamin D, Vascular Parathyroid Hormone Receptor Signaling, and Arteriosclerotic Calcium Accrual: Lessons Learned From Preclinical Models and Patients With End-Stage Renal Disease	560
Conclusions	480	Defining Cardiovascular Toxicity Thresholds for Vitamin D: Critical Clues From the Clinical Literature	561
References	481	Vitamin D, the Calcium-Sensing Receptor, and Cardiovascular Disease	561
		Summary, Conclusions, and Future Directions	562
		Acknowledgments	563
		References	563
81. Idiopathic Hypercalciuria and Nephrolithiasis		85. Vitamin D and Paget's Disease	
MURRAY J. FAVUS, MELTEM ZEYTINGLU AND FREDRIC L. COE		NORIYOSHI KURIHARA AND G. DAVID ROODMAN	
Introduction to Kidney Stones	485	Introduction	571
Idiopathic Hypercalciuria	487	Mechanism of Action of 1,25(OH) ₂ D ₃ on Osteoclast Formation	572
Current View of Human Genetic Hypercalciuria	498	Increased Levels of TAF12 in Osteoclast Precursors From Paget's Disease Patients Contribute to Their Hyperresponsivity to 1,25(OH) ₂ D ₃	572
Therapeutics of Idiopathic Hypercalciuria and Effects on Calcium Metabolism	498	TAF12 Expression Is Increased in Osteoclasts From Patients With Paget's Disease	573
Genetic Hypercalciuric Rats	500	Overexpression of TAF12 Is Sufficient to Induce 1,25(OH) ₂ D ₃ Hyperresponsivity in Human Osteoclast Precursors	574
Risk of Stone Formation Using Vitamin D Analogs	502	Mechanism of Action of TAF12 in the Increased 1,25(OH) ₂ D ₃ Responsivity of OCL Precursors From PD Patients	576
References	502	Marrow Stromal Cells Derived From p62 ^{P394L} Knock-In mice and p62 ^{P392L} Paget's Patients Are Hyperresponsive to 1,25(OH) ₂ D ₃ and Display Enhanced RANKL Production in Response to 1,25(OH) ₂ D ₃	576
Further Reading	505	Serum Concentrations of 1,25(OH) ₂ D ₃ in Paget's Patients	577
		Conclusion	577
		References	578
82. Hypercalcemia Due to Vitamin D Toxicity			
NATALIE E. CUSANO, SUSAN THYS-JACOBS AND JOHN P. BILEZIKIAN			
Introduction	507		
Forms of Exogenous Vitamin D Toxicity	508		
Forms of Endogenous Vitamin D Toxicity	511		
Clinical Manifestations	517		
Summary and Conclusions	519		
References	520		
83. The Hypocalcemic Disorders			
RACHEL I. GAFNI, KARL L. INSOGNA AND THOMAS O. CARPENTER			
Physiology	527		
Clinical Manifestations of Hypocalcemia	530		
Differential Diagnosis of Hypocalcemia	530		
Treatment of Hypocalcemia	538		
Conclusion	541		
Acknowledgments	541		
References	541		
84. Vitamin D: Cardiovascular Effects and Vascular Calcification			
CHRISTOPH ZECHNER AND DWIGHT A. TOWLER			
Introduction	549		
Vitamin D Signaling in Myocardial Remodeling and Function	550		
Vitamin D Actions in Atherosclerosis and Arteriosclerosis	552		
Vitamin D and Human Cardiovascular Disease: Compelling Epidemiology and Physiology, Emerging but Less Compelling Evidence of Interventional Benefit Still Persists	554		
Vitamin D Intoxication and Cardiovascular Calcification: Pharmacological Considerations	555		
The Impact of Calcium, Phosphate, and Vitamin D Excesses on Smooth Muscle Matrix Vesicle Physiology and Vascular Calcification	556		

IX

VITAMIN D ANALOGS

86. Analogs of Calcitriol			
LIEVE VERLINDEN, ROGER BOUILLON, PIERRE DE CLERCQ AND ANNEMIEKE VERSTUYF			
Introduction	583		
14-Epi Analogs of 1,25(OH) ₂ D ₃	584		
Decalin Analogs	587		
C- and D-Ring Analogs	588		
CF-Ring Analogs	600		
E-Ring Analogs	601		
Acyclic Analogs	601		
Nonsecosteroidal Compounds	601		
Gemini Analogs	609		
Conclusion	611		
References	611		

87. Nonsteroidal Ligands and Modulators of Vitamin D Receptor

RYAN E. STITES, JAMES G. MACKRELL AND KEITH R. STAYROOK

Introduction	615
CD-Ring-Replacement Ligands	616
Diarylmethane Ligands	618
Miscellaneous Nonsteroids	621
Nonsteroidal Modulators of Vitamin D Receptor-Coregulator Interactions	623
Perspectives	625
References	625

88. Bile Acid-Derived Vitamin D Receptor Ligands

MAKOTO MAKISHIMA AND SACHIKO YAMADA

The Vitamin D Receptor Is a Dual-Functional Receptor for Vitamin D and Bile Acids	629
Bile Acids and Nuclear Receptors	631
Development of Bile Acid Derivatives	635
X-Ray Crystal Structures of Vitamin D Receptor in Complex With Lithocholic Acid and Its Derivatives	637
Perspectives	641
References	641

89. Bifunctional Vitamin D Hybrid Molecules

JAMES L. GLEASON AND JOHN H. WHITE

Introduction	647
Combination Therapy and Bifunctional Agents	648
Nuclear Receptor Ligands as Trojan Horses	649
Vitamin D/Histone Deacetylase Inhibitor Hybrids	649
Nonsteroidal Hybrids	652
Non-HDACi Hybrids	652
Conclusion	653
References	653

90. Modulating Vitamin D Receptor-Coregulator Binding With Small Molecules

OLIVIA B. YU AND LEGGY A. ARNOLD

Introduction	657
Vitamin D Receptor Coactivators	657
Vitamin D Receptor Corepressors	658
Inhibiting Vitamin D Receptor: VDR Antagonists Versus VDR-Coregulator Inhibitors	659
Peptide-Based Inhibitors of Vitamin D Receptor-Coregulator Interactions	661
Small Molecule-Based Inhibitors of Vitamin D Receptor-Coregulator Interactions	663
Conclusion and Future Direction	664
Acknowledgment	664
References	664

91. Extended-Release Calcifediol in Renal Disease

MARTIN PETKOVICH AND CHARLES W. BISHOP

Introduction	667
Background—Vitamin D Signaling and Metabolism	668
Treating Secondary Hyperparathyroidism Associated With Vitamin D Insufficiency in Chronic Kidney Disease	670
Summary	674
Acknowledgments	674
References	674

92. Vitamin D Receptor Antagonists

HIROSHI SAITOH

Introduction	679
ZK Series	680
Adamantyl Derivatives	683
Lactam Derivatives	684
Amide Derivative	685
TEI-9647 and Its Derivatives	686
22-Alkyl Derivatives	689
Nonsteroidal Vitamin D Receptor Antagonist	690
Conclusion and Directions for Future Study	691
References	691

93. Eldecalcitol and Osteoporosis

TOSHIO MATSUMOTO AND FUMIAKI TAKAHASHI

Introduction	695
Structure-Function Relationship	696
Animal Studies	698
Effect on Other Tissues	701
Clinical Studies in Osteoporotic Patients	701
Acknowledgments	705
References	705

X

VITAMIN D AND CANCER

94. Overview of Vitamin D Actions in Cancer

MARJOLEIN VAN DRIEL, JOHANNES P.T.M. VAN LEEUWEN, ALBERTO MUÑOZ AND DAVID FELDMAN

Introduction	711
Vitamin D and Cancer	711
Vitamin D Effects on Tumor Cells	718
Combination Therapy	724
Resistance and Vitamin D Metabolism	726
Stimulation of Proliferation	727
Conclusions	728
References	728

95. Vitamin D Status and Cancer Incidence, Mortality, and Prognosis		Renal Cell Carcinoma	829
IRENE SHUI AND EDWARD GIOVANNUCCI		Summary	830
		References	831
		Further Reading	836
Introduction	743		
Cancer Incidence	744	99. Vitamin D and Colon Cancer	
Cancer Mortality and Survival	746	ANTONIO BARBÁCHANO, MARÍA JESÚS LARRIBA, GEMMA FERRER-MAYORGA, JOSÉ MANUEL GONZÁLEZ-SANCHO AND ALBERTO MUÑOZ	
References	753	Introduction	838
		Human Studies	841
96. Effects of Vitamin D Derivatives on Differentiation, Cell Cycle, and Apoptosis in Hematological Malignancies		Expression of Vitamin D Hydroxylases and the Vitamin D Receptor in Colon Cancer	842
GEORGE P. STUDZINSKI, ELZBIETA GOCEK, FREDERICK COFFMAN AND MICHAEL DANILENKO		Mechanism of Action of 1,25(OH) ₂ D ₃ in Colon Cancer	844
		Animal Models	852
Differentiation of Myeloid Leukemia Cells by Vitamin D Derivatives	762	Conclusions	855
Signaling and Execution of Monocytic Differentiation Induced by Vitamin D Derivatives	763	References	855
Transcription Factors in Vitamin D Derivative-Induced Differentiation	768		
Role of Micro-RNAs in Hematopoiesis, Differentiation, and Cell Cycle Block	769	100. Vitamin D and Skin Cancer	
Vitamin D Derivatives-Induced Progression of Monocytic to Macrophage Differentiation	770	KATHERINE J. RANSOHOFF, ERVIN H. EPSTEIN AND JEAN Y. TANG	
Effects of Vitamin D Derivatives on the Cell Cycle and Proliferation of Human Leukemia Cells	771	Introduction	863
Effects of Vitamin D Derivatives on Cell Survival and Cell Death	778	Two Sources of Vitamin D: Diet or Sunlight	863
Effects of Vitamin D Derivatives on Lymphoid Lineage Cells	779	Vitamin D and Indoor Tanning	865
Clinical Applications of Vitamin D Derivatives' Actions Against Hematopoietic Malignancies	780	UV Exposure Contributes to the Development of Melanoma and Nonmelanoma Skin Cancer	866
Conclusions	787	Vitamin D in Skin Cancer: Role of Vitamin D in Keratinocytes	867
References	787	Role of Vitamin D in Squamous Cell Carcinomas	867
		Role of Vitamin D in Basal Cell Carcinomas	868
97. Vitamin D Actions in Mammary Gland and Breast Cancer: Genomics, Metabolism, and Stem Cells		Role of Vitamin D in Melanoma	869
SARAH BEAUDIN AND JOELLEN WELSH		Photoprotection and Vitamin D Levels	870
		Conclusions	870
Introduction to Breast Cancer	802	References	870
Observational and Interventional Studies on Vitamin D and Breast Cancer	803		
Expression and Function of the Vitamin D Pathway in Normal and Neoplastic Breast Cells/Tissues	805	101. Vitamin D and Lung Cancer	
Impact of Vitamin D Signaling in Animal Models of Breast Cancer	807	TATIANA SHAUROVA, MUKUND SESHADRI AND PAMELA A. HERSHBERGER	
Genomic Profiling of Vitamin D Receptor Agonists in Breast Cancer Model Systems	809	Lung Cancer Overview	876
New Mechanistic Insight Into Vitamin D Actions in Breast Cancer	811	Etiology of Lung Cancer	876
Overall Conclusions and Remaining Research Questions	814	Vitamin D and Chronic Obstructive Pulmonary Disease	877
References	814	Variation in Vitamin D Signaling Pathway Components and Lung Cancer Risk/Outcomes	878
		Vitamin D and the Chemoprevention of Nonsmall Cell Lung Cancer	879
98. The Antitumor Effects of Vitamin D in Genitourinary Cancer		Vitamin D Actions in Nonsmall Cell Lung Cancer	880
DONALD L. TRUMP		Vitamin D-Based Combination Therapies for Advanced Nonsmall Cell Lung Cancer: Preclinical Rationale and Clinical Studies	884
		Activity of Calcitriol Analogs in Nonsmall Cell Lung Cancer Models	884
Introduction	821	Conclusions	885
Prostate Cancer	822	Acknowledgments	885
Bladder Cancer	828	References	885
		102. Vitamin D Inflammation and Cancer	
		ENIKÖ KALLAY AND LAURA BUBURUZAN	
		Introduction	892
		Vitamin D and the Vitamin D System	893

Inflammation	893	Vitamin D Pathway and Leprosy	959
Inflammation-Associated Cancer	896	History of Vitamin D, Sunshine, and Tuberculosis Treatment	960
Conclusions	904	Conclusion	961
References	904	References	961

XI

IMMUNITY, INFLAMMATION AND DISEASE

103. Vitamin D and Tuberculosis

ADRIAN R. MARTINEAU, DAVID A. JOLLIFFE AND JULIE DEMARET

Introduction	915
The Immune Response in Tuberculosis	916
Influence of Vitamin D on the Immune Response to <i>Mycobacterium tuberculosis</i>	916
Historical Studies	919
Studies With <i>Mycobacterium tuberculosis</i> Infection as an End Point	920
Studies With Active Tuberculosis Disease as End Point	921
Studies of Treatment Outcome	927
Conclusions	929
References	929

104. Vitamin D and Adaptive Immunology in Health and Disease

ELIZABETH H. MANN, PAUL E. PFEFFER AND CATHERINE M. HAWRYLOWICZ

Epidemiological Evidence for a Role of Vitamin D in Immune Disease	938
Actions of Vitamin D on Proinflammatory T Lymphocyte Responses	938
Actions of Vitamin D on Regulatory T Lymphocyte Responses	939
Actions of Vitamin D on B Lymphocytes	940
Actions of Vitamin D on the Immune Microenvironment and the Function of Antigen-Presenting Cells	940
Vitamin D and Vaccine Responses	941
Translational Studies as a Window to Study Effects of Vitamin D on Adaptive Immunology	942
Disparity Between Association, Translational, and Clinical Studies	942
Ultraviolet B Versus Oral Vitamin D Supplementation—Effects on the Adaptive Immune System	944
Vitamin D as a Temporal Regulator of Adaptive Immune Responses	944
Conclusions	944
References	945

105. Vitamin D and Innate Immunity

KATHRYN ZAVALA, ARIA VAZIRNIA AND PHILIP T. LIU

Introduction	951
Mycobacteria	951
Mechanisms for Pathogen Sensing	952
Barrier Function and Associated Infectious Diseases	954
Innate Immune Activity of 1,25-Dihydroxyvitamin D	954
Vitamin D Pathway and Tuberculosis	957

106. Vitamin D and Diabetes

AN-SOFIE VANHERWEGEN, CONNY GYSEMANS AND CHANTAL MATHIEU

Introduction	969
Vitamin D and Genetic Predisposition to Diabetes	970
Vitamin D, the Beta Cell, and Insulin Resistance in Type 2 Diabetes	971
Vitamin D as an Immune Modulator in Type 1 Diabetes	974
Conclusions and Clinical Perspectives	980
References	981

107. Vitamin D and Multiple Sclerosis

COLLEEN E. HAYES AND FAYE E. NASHOLD

Introduction	990
Genes and Environment in Multiple Sclerosis	991
Vitamin D and Multiple Sclerosis Risk and Severity	992
Vitamin D Signaling in the Immune and Nervous Systems	995
Vitamin D Mechanisms of Immune Regulation	997
Vitamin D Mechanisms of Neuroprotection	1000
Rising Multiple Sclerosis Incidence in Women	1002
Sex-Based Differences in Multiple Sclerosis and the Role of Estrogen	1002
Vitamin D and Estrogen Synergy for T Cell Self-Tolerance	1003
Declining Vitamin D Status and Rising Multiple Sclerosis Incidence	1005
Vitamin D and Multiple Sclerosis Prevention	1007
Conclusions and Unanswered Questions	1009
Acknowledgments	1009
References	1010

108. Vitamin D and Inflammatory Bowel Disease

MARGHERITA T. CANTORNA AND DANNY BRUCE

Introduction	1025
What Is Inflammatory Bowel Disease?	1025
Who Gets Inflammatory Bowel Disease?	1026
The Gut Epithelium, Commensals, and Inflammatory Bowel Disease	1028
The Immune Response and Inflammatory Bowel Disease	1028
Vitamin D Regulates T Cell Responsiveness	1029
Experimental Models of Inflammatory Bowel Disease	1030
Vitamin D and the Microbiota	1031
Current Treatments for Inflammatory Bowel Disease	1032
Vitamin D as a Treatment Option for Inflammatory Bowel Disease	1033
Conclusions	1033
References	1033

109. Psoriasis and Other Skin Diseases

JÖRG REICHRATH AND MICHAEL F. HOLICK

Introduction/Historical Overview	1037
Pathogenesis of Psoriasis	1038

The Vitamin D System in Normal and Psoriatic Skin	1038	Vitamin D and Lung Development	1099
Physiological and Pharmacological Actions of Vitamin D Analogs in Normal and Psoriatic Skin	1040	Vitamin D and Acute Respiratory Infection	1100
Clinical Use of 1,25(OH) ₂ D ₃ and Its Analogs in Psoriasis and Other Skin Diseases	1043	Vitamin D and Asthma	1103
Vitamin D Analog Therapy in Other Skin Diseases	1045	Vitamin D and Chronic Obstructive Pulmonary Disease	1107
Evaluation of New Vitamin D Analogs, With Less Calcemic Activity, Which Can Be Used for the Treatment of Hyperproliferative Skin Disorders	1046	Potential Mechanisms	1109
Conclusion	1047	Future Research	1112
References	1047	Summary	1114
		Acknowledgments	1114
		References	1114

XII

THERAPEUTIC APPLICATIONS AND NEW ADVANCES

110. Sunlight Protection by Vitamin D Compounds

REBECCA S. MASON, MARK S. RYBCHYN AND KATIE M. DIXON

Introduction	1056
DNA Damage by Ultraviolet Radiation	1056
DNA Repair	1058
Ultraviolet-Induced Immune Suppression	1060
Synthesis and Metabolism of Vitamin D Compounds in Skin	1061
The Vitamin D System and Photocarcinogenesis	1061
Vitamin D Compounds Reduce Several Types of Ultraviolet-Induced DNA Damage	1063
Vitamin D Compounds and UV-Induced Immune Suppression	1065
Pathways—Evidence for Involvement of Nonclassical Pathways	1066
Conclusions	1068
References	1069

111. Vitamin D, Cardiovascular Disease, and Hypertension

STEFAN PILZ

Introduction	1077
Historical Perspective	1078
Mechanistic Effects	1078
Observational Studies	1080
Mendelian Randomization Studies	1082
Randomized Controlled Trials	1083
Future Perspective	1085
Conclusions	1086
References	1087

112. Vitamin D, Acute Respiratory Infection, and Asthma/Chronic Obstructive Pulmonary Disease

CARLOS A. CAMARGO JR.

Introduction	1096
Common Respiratory Disorders	1096

113. Vitamin D and Muscle Performance in Athletes

LISA CEGLIA AND ROBERTO TONI

Introduction	1121
Historical Links Between Vitamin D and Athletic Performance	1121
Basic Research Influencing Interest in Vitamin D in Athletic Performance	1122
Clinical Research Influencing Interest in Vitamin D in Athletic Performance	1124
Recent Clinical Research in Athletes	1124
Conclusion	1127
References	1127

114. Vitamin D: Presence and Function in the Eye

JAWAHER A. ALSALEM, SAAEHA RAUZ AND GRAHAM R. WALLACE

Introduction	1131
Vitamin D and the Eye	1132
Ocular Infection	1133
Dry Eye Disease	1133
Cataract	1135
Glaucoma	1136
Uveitis	1136
Age-Related Macular Degeneration	1138
Diabetic Retinopathy	1141
Conclusion	1142
References	1143

115. Adult Vitamin D Deficiency and Adverse Brain Outcomes

NATALIE J. GROVES, JOHN J. MCGRATH AND THOMAS H.J. BURNE

Introduction	1147
Epidemiology	1147
Preclinical Studies	1151
Future Directions	1154
Conclusion	1155
References	1155

116. Vitamin D in Pregnancy and Lactation: Moving Into the Future

BRUCE W. HOLLIS AND CAROL L. WAGNER

Introduction	1159
Vitamin D Nomenclature and Metabolism	1160
Vitamin D Metabolism During Pregnancy When Compared With the Nonpregnant State Including Lactation	1160

CONTENTS

Obstetrical “Paranoia” Regarding Vitamin D Administration During Pregnancy	1162	Vitamin D Deficiency Risk Factors in the Critically Ill Patients	1178
Observational Studies Suggesting the Function of Vitamin D Extended Beyond Calcium Homeostasis During Pregnancy	1162	Vitamin D Mechanism in Critical Illness	1179
Randomized Controlled Trials Investigating Vitamin D Supplementation During Pregnancy	1163	Antimicrobial Peptides	1180
Supplementing Vitamin D During Pregnancy to Prevent Childhood Asthma	1165	β-Defensin 2	1181
Neurodevelopment and Autoimmune Consequences	1168	Cathelicidin	1181
Current Recommendation for Vitamin D Supplementation During Pregnancy	1168	Inflammasome Activation	1181
Vitamin D Requirements of the Mother/Infant Dyad During Lactation	1169	Metabolomics, Transcriptomics, and Epigenetics of Vitamin D	1182
Altering the Vitamin D Content of Human Milk	1169	Assay	1183
Interventional and RCTs to Determine if Maternal Vitamin D Supplementation Can Supply Adequate Vitamin D to the Nursing Infant	1169	Observational Data	1183
Current Recommendation for Maternal Vitamin D Supplementation During Lactation	1171	Vitamin D and Critical Illness Outcomes	1183
Summary	1171	Sepsis	1183
Financial Support	1172	Acute Kidney Injury	1183
References	1172	Acute Lung Injury	1184
		Interventional Data	1184
		Dose in Critical Illness	1186
		Is Vitamin D Supplementation Safe?	1186
		Conclusions	1187
		References	1187
		Index for Volume 2	1195

117. Vitamin D and Critically Ill Intensive Care Unit Patients

KENNETH B. CHRISTOPHER

Introduction	1177
Prevalence of Vitamin D Deficiency in the Critically Ill Patients	1178

This page intentionally left blank

List of Contributors

- John S. Adams** David Geffen School of Medicine at UCLA, Los Angeles, CA, United States
- Judith E. Adams** Central Manchester University Hospital NHS Foundation Trust, Manchester, United Kingdom; University of Manchester, Manchester, United Kingdom
- Jawaher A. Alsalem** University of Birmingham, Birmingham, United Kingdom
- Paul H. Anderson** University of South Australia, Adelaide, SA, Australia
- Panagiota Andreopoulou** Hospital for Special Surgery, New York, NY, United States
- Edith Angellotti** Tufts Medical Center, Boston, MA, United States
- Leggy A. Arnold** University of Wisconsin-Milwaukee, Milwaukee, WI, United States
- Gerald J. Atkins** University of Adelaide, Adelaide, SA, Australia
- Antonio Barbáchano** Universidad Autónoma de Madrid (UAM), CIBER de Cáncer (CIBERONC), Madrid, Spain
- Shari S. Bassuk** Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
- Sarah Beaudin** University at Albany, Rensselaer, NY, United States
- Anna Y. Belorusova** Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC)/Institut National de Santé et de Recherche Médicale (INSERM) U964/Centre National de Recherche Scientifique (CNRS) UMR 7104/Université de Strasbourg, Illkirch, France
- Nancy A. Benkusky** University of Wisconsin-Madison, Madison, WI, United States
- Carlos Bernal-Mizrachi** Washington University, Saint Louis, MO, United States
- Ishir Bhan** Harvard Medical School, Boston, MA, United States
- Harjit P. Bhattoa** University of Debrecen, Debrecen, Hungary
- Daniel D. Bikle** University of California San Francisco, San Francisco, CA, United States
- John P. Bilezikian** Columbia University College of Physicians and Surgeons, New York, NY, United States
- Neil C. Binkley** University of Wisconsin-Madison, Madison, WI, United States
- Heike A. Bischoff-Ferrari** University Hospital Zurich, Zurich, Switzerland
- Charles W. Bishop** OPKO Health, Miami, FL, United States
- Ida M. Boisen** University of Copenhagen, København, Denmark; Harvard School of Dental Medicine, Boston, MA, United States
- Fabrizio Bonelli** R&D DiaSorin Inc., Stillwater, MN, United States
- Adele L. Boskey** Hospital for Special Surgery, New York, NY, United States; Weill Medical College, New York, NY, United States; Graduate School of Cornell University, New York, NY, United States
- Barbara J. Boucher** Queen Mary University of London, London, United Kingdom
- Roger Bouillon** Katholieke Universiteit Leuven, Leuven, Belgium
- Manuella Bouttier** McGill University, Montreal, QC, Canada
- Barbara D. Boyan** Georgia Tech and Emory University, Atlanta, GA, United States; Virginia Commonwealth University, Richmond, VA, United States
- Danny Bruce** Pennsylvania State University, University Park, PA, United States; University of North Carolina, Chapel Hill, NC, United States
- Laura Buburuzan** University of Bucharest, Bucharest, Romania
- Andrew J. Burghardt** University of California, San Francisco, CA, United States
- Thomas H.J. Burne** The University of Queensland, St. Lucia, QLD, Australia; The Park Centre for Mental Health, Wacol, QLD, Australia
- Mona S. Calvo** U.S. Food and Drug Administration, Silver Spring, MD, United States
- Carlos A. Camargo Jr.** Harvard Medical School, Boston, MA, United States
- Jorge B. Cannata-Andia** Hospital Universitario Central de Asturias, Oviedo, Spain
- Margherita T. Cantorna** Pennsylvania State University, University Park, PA, United States; University of North Carolina, Chapel Hill, NC, United States
- Carsten Carlberg** University of Eastern Finland, Kuopio, Finland
- Geert Carmeliet** Katholieke Universiteit Leuven, Leuven, Belgium
- Thomas O. Carpenter** Yale University School of Medicine, New Haven, CT, United States
- Graham D. Carter** Charing Cross Hospital, London, United Kingdom
- Kevin D. Cashman** University College Cork, Cork, Ireland
- Lisa Ceglia** Tufts University, Boston, MA, United States
- Sylvia Christakos** Rutgers, The State University of New Jersey, Newark, NJ, United States
- Kenneth B. Christopher** Harvard Medical School, Boston, MA, United States
- Rene F. Chun** David Geffen School of Medicine at UCLA, Los Angeles, CA, United States

- Fredric L. Coe** The University of Chicago Pritzker School of Medicine, Chicago, IL, United States
- Frederick Coffman** Rutgers School of Health Professions, Newark, NJ, United States
- Juliet Compston** Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
- Cyrus Cooper** University of Southampton, Southampton General Hospital, Southampton, United Kingdom
- Elizabeth M. Curtis** University of Southampton, Southampton General Hospital, Southampton, United Kingdom
- Natalie E. Cusano** Columbia University College of Physicians and Surgeons, New York, NY, United States
- Michael Danilenko** Ben-Gurion University of the Negev, Beer-Sheva, Israel
- G. David Roodman** Indiana University, Indianapolis, IN, United States; Roudebush VA Medical Center, Indianapolis, IN, United States
- Bess Dawson-Hughes** Tufts University, Boston, MA, United States
- Pierre De Clercq** Universiteit Gent, Gent, Belgium
- Hector F. DeLuca** University of WI-Madison, Madison, WI, United States
- Julie Demaret** Queen Mary University of London, London, United Kingdom
- Marie B. Demay** Harvard Medical School, Boston, MA, United States
- David W. Dempster** Columbia University, New York, NY, United States
- Elaine M. Dennison** University of Southampton, Southampton General Hospital, Southampton, United Kingdom
- Puneet Dhawan** Rutgers, The State University of New Jersey, Newark, NJ, United States
- Vassil Dimitrov** McGill University, Montreal, QC, Canada
- Katie M. Dixon** University of Sydney, Sydney, NSW, Australia
- Maryam Doroudi** Georgia Tech and Emory University, Atlanta, GA, United States
- Shevaun M. Doyle** Hospital for Special Surgery, New York, NY, United States
- Adriana S. Dusso** Hospital Universitario Central de Asturias, Oviedo, Spain
- Aleksey Dvorzhinskiy** Hospital for Special Surgery, New York, NY, United States
- Peter R. Ebeling** Monash University Melbourne, Clayton, VIC, Australia
- John A. Eisman** Garvan Institute of Medical Research, Sydney, NSW, Australia
- Gregory R. Emkey** Pennsylvania Regional Center for Arthritis & Osteoporosis Research, Wyomissing, PA, United States
- Ervin H. Epstein Jr.** Children's Hospital Oakland Research Institute, Oakland, CA, United States
- Sol Epstein** University of Pennsylvania, Philadelphia, PA, United States
- Darryl Eyles** The University of Queensland, St. Lucia, QLD, Australia; The Park Centre for Mental Health, Wacol, QLD, Australia
- Murray J. Favus** The University of Chicago Pritzker School of Medicine, Chicago, IL, United States
- David Feldman** Stanford University School of Medicine, Stanford, CA, United States
- Gemma Ferrer-Mayorga** Universidad Autónoma de Madrid (UAM), CIBER de Cáncer (CIBERONC), Madrid, Spain
- David M. Findlay** University of Adelaide, Adelaide, SA, Australia
- James C. Fleet** Purdue University, West Lafayette, IN, United States
- Brian L. Foster** The Ohio State University, Columbus, OH, United States
- Renny T. Franceschi** University of Michigan, Ann Arbor, MI, United States
- David R. Fraser** The University of Sydney, Sydney, NSW, Australia
- Jessica M. Furst** Columbia University Medical Center, New York, NY, United States
- Rachel I. Gafni** National Institutes of Health, Bethesda, MD, United States
- Edward Giovannucci** Harvard TH Chan School of Public Health, Boston, MA, United States; Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States
- Christian M. Girgis** Westmead Hospital, Sydney, NSW, Australia; Royal North Shore Hospital, Sydney, NSW, Australia; University of Sydney, Sydney, NSW, Australia
- James L. Gleason** McGill University, Montreal, QC, Canada
- Francis H. Glorieux** Shriners Hospitals for Children – Canada, Montreal, QC, Canada
- Elzbieta Gocek** Rutgers, The State University of New Jersey, Newark, NJ, United States; University of Wroclaw, Wroclaw, Poland
- David Goltzman** McGill University Health Centre, McGill University, Montreal, QC, Canada
- José Manuel González-Sancho** Universidad Autónoma de Madrid (UAM), CIBER de Cáncer (CIBERONC), Madrid, Spain
- Laura A. Graeff-Armas** University of Nebraska Medical Center, Omaha, NE, United States
- William B. Grant** Sunlight, Nutrition, and Health Research Center, San Francisco, CA, United States
- Natalie J. Groves** The University of Queensland, St. Lucia, QLD, Australia
- Conny Gysemans** KU Leuven, Leuven, Belgium

- Lasse Bøllehuus Hansen** University of Copenhagen, København, Denmark; Harvard School of Dental Medicine, Boston, MA, United States
- Nicholas C. Harvey** University of Southampton, Southampton General Hospital, Southampton, United Kingdom
- Catherine M. Hawrylowicz** King's College London, London, United Kingdom
- Colleen E. Hayes** University of Wisconsin–Madison, Madison, WI, United States
- Robert P. Heaney** Creighton University, Omaha, NE, United States
- Geoffrey N. Hendy** McGill University Health Centre, McGill University, Montreal, QC, Canada
- Pamela A. Hershberger** Roswell Park Cancer Institute, Buffalo, NY, United States
- Martin Hewison** The University of Birmingham, Birmingham, United Kingdom
- Michael F. Holick** Boston University School of Medicine, Boston, MA, United States
- Bruce W. Hollis** Medical University of South Carolina, Charleston, SC, United States
- Philippe P. Hujuel** University of Washington, Seattle, WA, United States
- Elina Hyppönen** University of South Australia, Adelaide, Australia
- Karl L. Insogna** Yale University School of Medicine, New Haven, CT, United States
- Nina G. Jablonski** The Pennsylvania State University, University Park, PA, United States
- Martin Blomberg Jensen** University of Copenhagen, København, Denmark; Harvard School of Dental Medicine, Boston, MA, United States
- David A. Jolliffe** Queen Mary University of London, London, United Kingdom
- Glennville Jones** Queen's University, Kingston, ON, Canada
- Kerry S. Jones** MRC Human Nutrition Research, Cambridge, United Kingdom
- Harald Jüppner** Massachusetts General Hospital, Boston, MA, United States
- Enikő Kallay** Medical University of Vienna, Währinger Gürtel, Vienna
- Andrew C. Karaplis** McGill University Health Centre, McGill University, Montreal, QC, Canada
- Martin Kaufmann** Queen's University, Kingston, ON, Canada
- Mairead Kiely** University College Cork, Cork, Ireland
- Tiffany Y. Kim** University of California, San Francisco, San Francisco, CA, United States; San Francisco Veterans Affairs Health Care System, San Francisco, CA, United States
- Martin Konrad** University Children's Hospital Münster, Münster, Germany
- Christopher S. Kovacs** Health Sciences Centre, St. John's, NL, Canada
- Richard Kremer** McGill University Health Centre, McGill University, Montreal, QC, Canada
- Roland Krug** University of California, San Francisco, CA, United States
- Rajiv Kumar** Mayo Clinic College of Medicine, Rochester, MN, United States
- Noriyoshi Kurihara** Indiana University, Indianapolis, IN, United States
- Emma Laing** University of Georgia, Athens, GA, United States
- Joseph M. Lane** Hospital for Special Surgery, New York, NY, United States
- Dean P. Lerner** The University of Birmingham, Birmingham, United Kingdom
- María Jesús Larriba** Universidad Autónoma de Madrid (UAM), CIBER de Cáncer (CIBERONC), Madrid, Spain
- Gilles Laverny** Institute of Genetics and Molecular and Cellular Biology (IGBMC), Institut National de Santé et de Recherche Médicale (INSERM) U964/Centre National de Recherche Scientifique (CNRS) UMR 7104/Université de Strasbourg, Illkirch, France
- Nathalie Le Roy** INRA, UR83 Recherches avicoles, Fonction et Régulation des protéines de l'œuf, Développement de l'œuf, Valorisation, Évolution, Nouzilly, France
- Seong M. Lee** University of Wisconsin-Madison, Madison, WI, United States
- Michael A. Levine** The Children's Hospital of Philadelphia and the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States
- Richard Lewis** University of Georgia, Athens, GA, United States
- Paul Lips** VU University Medical Center, Amsterdam, The Netherlands
- Thomas S. Lisse** University of Maine GSBSE (Graduate School of Biomedical Sciences and Engineering), Bar Harbor, ME, United States
- Eva S. Liu** Massachusetts General Hospital, Boston, MA, United States
- Philip T. Liu** University of California, Los Angeles, CA, United States
- Yan Li** University of Michigan, Ann Arbor, MI, United States
- Yan Chun Li** The University of Chicago, Chicago, IL, United States
- James G. MacKrell** Lilly Research Laboratories, Indianapolis, IN, United States
- Leila J. Mady** Rutgers, The State University of New Jersey, Newark, NJ, United States
- Sharmila Majumdar** University of California, San Francisco, CA, United States
- Makoto Makishima** Nihon University School of Medicine, Tokyo, Japan

- Peter J. Malloy** Stanford University School of Medicine, Stanford, CA, United States
- Elizabeth H. Mann** King's College London, London, United Kingdom; The Francis Crick Institute, London, United Kingdom
- JoAnn E. Manson** Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States; Harvard T.H. Chan School of Public Health, Boston, MA, United States
- Adrian R. Martineau** Queen Mary University of London, London, United Kingdom
- Rebecca S. Mason** University of Sydney, Sydney, NSW, Australia
- Chantal Mathieu** KU Leuven, Leuven, Belgium
- Toshio Matsumoto** University of Tokushima, Tokushima, Japan
- Donald G. Matthews** University at Albany, Rensselaer, NY, United States; Oregon Health and Science University, Portland, OR, United States
- John J. McGrath** The University of Queensland, St. Lucia, QLD, Australia; The Park Centre for Mental Health, Wacol, QLD, Australia
- Daniel Metzger** Institute of Genetics and Molecular and Cellular Biology (IGBMC), Institut National de Santé et de Recherche Médicale (INSERM) U964/Centre National de Recherche Scientifique (CNRS) UMR 7104/Université de Strasbourg, Illkirch, France
- Mark B. Meyer** University of Wisconsin-Madison, Madison, WI, United States
- Denshun Miao** McGill University Health Centre, McGill University, Montreal, QC, Canada
- Mathew T. Mizwicki** University of California, Riverside, CA, United States
- Rebecca J. Moon** University of Southampton, Southampton General Hospital, Southampton, United Kingdom
- Howard A. Morris** University of South Australia, Adelaide, SA, Australia
- Li J. Mortensen** University of Copenhagen, København, Denmark; Harvard School of Dental Medicine, Boston, MA, United States
- Alberto Muñoz** Universidad Autónoma de Madrid (UAM), CIBER de Cáncer (CIBERONC), Madrid, Spain
- Yuko Nakamichi** Matsumoto Dental University, Shiojiri, Japan
- Carmen J. Narvaez** University at Albany, Rensselaer, NY, United States
- Faye E. Nashold** University of Wisconsin-Madison, Madison, WI, United States
- Tally Naveh-Manly** Hadassah Hebrew University Medical Center, Jerusalem, Israel
- Carrie M. Nielson** Oregon Health & Science University, Portland, OR, United States
- Anthony W. Norman** University of California, Riverside, CA, United States
- Yves Nys** INRA, UR83 Recherches avicoles, Fonction et Régulation des protéines de l'œuf, Développement de l'œuf, Valorisation, Évolution, Nouzilly, France
- Melda Onal** University of Wisconsin-Madison, Madison, WI, United States
- Lubna Pal** Yale University School of Medicine, New Haven, CT, United States
- Kristine Y. Patterson** U.S. Department of Agriculture, Beltsville, MD, United States
- Steven Pauwels** Katholieke Universiteit Leuven, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium
- Pamela R. Pehrsson** U.S. Department of Agriculture, Beltsville, MD, United States
- Martin Petkovich** Queen's University, Kingston, ON, Canada
- John M. Pettifor** University of the Witwatersrand, Johannesburg, South Africa
- Paul E. Pfeffer** King's College London, London, United Kingdom; Barts Health NHS Trust, London, United Kingdom
- Katherine M. Phillips** Virginia Tech, Blacksburg, VA, United States
- J. Wesley Pike** University of Wisconsin-Madison, Madison, WI, United States
- Stefan Pilz** Medical University of Graz, Graz, Austria
- Anastassios G. Pittas** Tufts Medical Center, Boston, MA, United States
- Pawel Pludowski** The Children's Memorial Health Institute, Warsaw, Poland
- David E. Prosser** Queen's University, Kingston, ON, Canada
- Sri Ramulu N. Pullagura** University of Maine GSBSE (Graduate School of Biomedical Sciences and Engineering), Bar Harbor, ME, United States
- L. Darryl Quarles** University of Tennessee Health Science Center, Memphis, TN, United States
- Rithwick Rajagopal** Washington University, Saint Louis, MO, United States
- Katherine J. Ransohoff** Stanford University Medical Center, Redwood City, CA, United States
- Saaha Rauz** University of Birmingham, Birmingham, United Kingdom
- Brian J. Rebolledo** Hospital for Special Surgery, New York, NY, United States
- Jörg Reichrath** The Saarland University Hospital, Homburg, Germany; Boston University Medical Center, Boston, MA, United States
- Sandra Rieger** Kathryn W. Davis Center for Regenerative Biology and Medicine, Salisbury Cove, ME, United States
- Amy E. Riek** Washington University, Saint Louis, MO, United States
- Natacha Rochel** Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC)/Institut National de Santé et de Recherche Médicale (INSERM) U964/Centre National de Recherche Scientifique (CNRS) UMR 7104/Université de Strasbourg, Illkirch, France

- Jeffrey D. Roizen** The Children's Hospital of Philadelphia and the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States
- Janet M. Roseland** U.S. Department of Agriculture, Beltsville, MD, United States
- Cliff Rosen** Maine Medical Center Research Institute-Scarborough, ME, United States
- Mark S. Rybchyn** University of Sydney, Sydney, NSW, Australia
- Hiroshi Saitoh** Teijin Institute for Bio-medical Research, Tokyo, Japan
- Reyhaneh Salehi-Tabar** McGill University, Montreal, QC, Canada
- Anne L. Schafer** University of California, San Francisco, San Francisco, CA, United States; San Francisco Veterans Affairs Health Care System, San Francisco, CA, United States
- Karl P. Schlingmann** University Children's Hospital Münster, Münster, Germany
- Inez Schoenmakers** MRC Human Nutrition Research, Cambridge, United Kingdom; University of East Anglia, Norwich, United Kingdom
- Zvi Schwartz** Virginia Commonwealth University, Richmond, VA, United States
- Kayla Scott** Virginia Commonwealth University, Richmond, VA, United States
- Christopher T. Sempos** National Institutes of Health, Bethesda, MD, United States; University of Wisconsin-Madison, Madison, WI, United States
- Lusia Sepiashvili** Mayo Clinic, Rochester, MN, United States
- Mukund Seshadri** Roswell Park Cancer Institute, Buffalo, NY, United States
- Elizabeth Shane** Columbia University Medical Center, New York, NY, United States
- Tatiana Shaurova** Roswell Park Cancer Institute, Buffalo, NY, United States
- Irene Shui** Harvard School of Public Health, Boston, MA, United States
- Justin Silver** Hadassah Hebrew University Medical Center, Jerusalem, Israel
- Ravinder J. Singh** Mayo Clinic, Rochester, MN, United States
- Linda Skingle** Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
- René St-Arnaud** Shriners Hospitals for Children – Canada, Montreal, QC, Canada
- Jessica Starr** Columbia University Medical Center, New York, NY, United States
- Keith R. Stayrook** Lilly Research Laboratories, Indianapolis, IN, United States
- Emily M. Stein** Columbia University Medical Center, New York, NY, United States
- Ryan E. Stites** Lilly Research Laboratories, Indianapolis, IN, United States
- George P. Studzinski** Rutgers, The State University of New Jersey, Newark, NJ, United States
- Tatsuo Suda** Saitama Medical University, Saitama, Japan
- Fumiaki Takahashi** Chugai Pharmaceutical Co. Ltd., Tokyo, Japan
- Naoyuki Takahashi** Matsumoto Dental University, Shiojiri, Japan
- Jean Y. Tang** Stanford University Medical Center, Redwood City, CA, United States
- Christine L. Taylor** National Institutes of Health, Bethesda, MD, United States
- Hugh S. Taylor** Yale University School of Medicine, New Haven, CT, United States
- Peter J. Tebben** Mayo Clinic College of Medicine, Rochester, MN, United States
- Thomas D. Thacher** Mayo Clinic, Rochester, MN, United States
- Ravi Thadhani** Harvard Medical School, Boston, MA, United States
- Kebashni Thandrayen** University of the Witwatersrand, Johannesburg, South Africa; Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa
- Susan Thys-Jacobs** Columbia University College of Physicians and Surgeons, New York, NY, United States
- Dov Tiosano** Meyer Children's Hospital, Haifa, Israel
- Roberto Toni** Tufts University, Boston, MA, United States; University of Parma School of Medicine, Parma, Italy; Academy of Sciences of Bologna, Bologna, Italy
- Dwight A. Towler** UT Southwestern Medical Center, Dallas, TX, United States
- Donald L. Trump** Inova Schar Cancer Institute, Fairfax, VA, United States
- Nobuyuki Udagawa** Matsumoto Dental University, Shiojiri, Japan
- André G. Uitterlinden** Erasmus Medical Centre, Rotterdam, The Netherlands
- Aasis Unnanuntana** Hospital for Special Surgery, New York, NY, United States; Mahidol University, Bangkok, Thailand
- Jeroen van de Peppel** Erasmus Medical Centre, Rotterdam, The Netherlands
- Bram C.J. van der Eerden** Erasmus Medical Centre, Rotterdam, The Netherlands
- Marjolein van Driel** Erasmus MC, Rotterdam, The Netherlands
- Johannes P.T.M. van Leeuwen** Erasmus MC, Rotterdam, The Netherlands
- Natasja van Schoor** VU University Medical Center, Amsterdam, The Netherlands
- An-Sofie Vanherwegen** KU Leuven, Leuven, Belgium
- Aria Vazirnia** University of California, San Diego, CA, United States
- Lieve Verlinden** Katholieke Universiteit Leuven, Leuven, Belgium

- Annemieke Verstuyf** Katholieke Universiteit Leuven, Leuven, Belgium
- Reinhold Vieth** University of Toronto, Toronto, ON, Canada
- Carol L. Wagner** Medical University of South Carolina, Charleston, SC, United States
- Graham R. Wallace** University of Birmingham, Birmingham, United Kingdom
- Connie Weaver** Purdue University, West Lafayette, IN, United States
- JoEllen Welsh** University at Albany, Rensselaer, NY, United States
- John H. White** McGill University, Montreal, QC, Canada
- Susan J. Whiting** University of Saskatchewan, Saskatoon, SK, Canada
- Michael P. Whyte** Washington University School of Medicine at Barnes-Jewish Hospital, St Louis, MO, United States
- John J. Wysolmerski** Yale University School of Medicine, New Haven, CT, United States
- Sachiko Yamada** Nihon University School of Medicine, Tokyo, Japan
- Olivia B. Yu** University of Wisconsin-Milwaukee, Milwaukee, WI, United States
- Kathryn Zavala** University of California, Los Angeles, CA, United States
- Christoph Zechner** UT Southwestern Medical Center, Dallas, TX, United States
- Meltem Zeytinoglu** The University of Chicago Pritzker School of Medicine, Chicago, IL, United States
- Hengguang Zhao** The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

IN MEMORIAM

ROBERT P. HEANEY MD (1928–2016)



The field of bone/vitamin D research lost an iconic figure on August 6, 2016 when Dr. Robert P. Heaney died at age 88. Death was due to a brain tumor, which he had battled for more than a year. However, in true Heaney character, he had been returning to the laboratory several days each week, analyzing data, producing research papers, and providing advice and mentoring.

Dr. Heaney obtained his undergraduate and medical training (1951) at Creighton University in Omaha, NE and completed internship and residency in Internal Medicine at St. Louis University. His postgraduate training included a Public Health Service Postdoctoral Fellowship at the National Cancer Institute. He also was a Clinical Associate at the National Institute of Arthritis and Metabolic Diseases for 2 years. In 1957, he returned to Creighton University, as Assistant Professor, where he had an illustrious career as a scientist, while also serving in various administrative positions, including Vice President for Health Sciences. Since 1984 he was the holder of the John A. Creighton University Professorship. In 2013 Creighton University recognized Dr. Heaney with an award for Lifetime Achievement in Research.

Dr. Heaney's productivity was legend. He authored or coauthored more than 1000 papers, abstracts, review articles, books, book chapters, editorials, letters, and book reviews. His first scientific paper was published in 1956 in the journal, *Cancer*. It described the results of treatment with 6-mercaptopurine in human leukemia. Beginning in 1958, he published radiocalcium studies of bone formation, calcium absorption, calcium balance, bone loss, and calcium physiology in humans. This work formed the basis for recommended dietary calcium intakes for pre- and postmenopausal women. In 2008, the National Osteoporosis Foundation recognized Dr. Heaney with the first "Legends of Osteoporosis" award for his contributions to the field of osteoporosis. He focused widespread attention on the importance of osteoporosis and in recognition of this he was presented a lifetime achievement award from the US House of Representatives on November 10, 2015. In some circles, he is referred to as the "Grandfather of Osteoporosis."

By 1982 Dr. Heaney added vitamin D research to his focus, which he pursued vigorously to the end. He understood the importance of vitamin D for skeletal health but was especially captivated by the discovery of the vitamin D receptor and, subsequently, the nonskeletal effects of vitamin D. He was adamant about the importance of eliminating vitamin D deficiency in human populations and took part in many debates about the levels of serum 25(OH)D needed for optimal health (usually arguing for the higher levels). During the later years of his career, he produced prolific writings on vitamin D physiology, optimal vitamin D intake, and the definition of vitamin D deficiency. In 2012 he was presented a Career Award at the 15th Workshop on Vitamin D.

Dr. Heaney recognized that published clinical vitamin D studies were often flawed, rendering interpretation of findings erroneous or inconclusive. His concern was that the traditional randomized controlled trials of nutritional supplements were inappropriate because it was impossible to have a true placebo group in which no one consumed the nutrient in his/her diet. Thus such trials were probably biased toward a "null" outcome. Dr. Heaney wrote many "persuasive" papers addressing this concern.

He passionately believed that scientific biomedical findings that benefit health needed to be communicated to the public. He often pointed out that "no research project is completed until the findings are disseminated." To this end, he published papers and accepted innumerable speaking engagements throughout the world.

Dr. Heaney's achievements have been widely recognized and his awards include the Frederic C Bartter Award from the American Society for Bone and Mineral Research, the Kappa Delta Award from the American College of Orthopedic Surgeons, the E.V. McConnell Award from American Society for Clinical and Nutrition, and the institute CANDIA Scientific Prize from France.

Dr. Heaney has mentored a large number of people including the authors of this memorial. His mentorship has been inspirational for our students, residents, and fellows at Creighton University as well as similar trainees in other institutions. He has been an enthusiastic, passionate teacher of medicine and bone pathology and physiology.

Dr. Heaney was very active in Creighton University's spiritual community. He was well known for his passion for the scripture and his contributions to "Daily Reflections" on the Creighton website. His spiritual writings have been a source of great inspiration for persons at Creighton University and beyond. He also wrote for a monthly Catholic magazine "America". Shortly before his death, he wrote a poignant piece, "Final Words," for the Creighton Magazine. <http://www.creighton.edu/creightonmagazine/2016smranewsheaney/>.

Dr. Heaney and his late wife, Barbara, raised 7 children, and at his death his descendants include 14 grandchildren and 3 great grandchildren. They all were a source of great pride and

much enjoyment for him. Dr. Heaney will be remembered as a healer, a thinker, and a man of grace and generosity. We are all greatly saddened by his loss, and we offer our special support to his wife, Janet.

Robert R. Recker, MD
Joan M. Lappe, PhD

MILAN USKOKOVIC PHD (1924–2015)



Dr. Milan Uskokovic, who made major contributions to the vitamin D scientific community, died on May 11, 2015 in Towson, Maryland, just 5 weeks after the death of his beloved wife, Nada. Born in Belgrade, Yugoslavia, on July 14, 1924, he met Nada at the Belgrade Polytechnic University where both studied chemical engineering. They immigrated to the United States after he received a scholarship to study organic chemistry at Clark University. He received his PhD from the Worcester Foundation of Experimental Biology at Clark University in 1960 and joined Hoffmann La Roche in Nutley as a senior scientist. From 1973 to 1995, he led the Roche Natural Products Department and established syntheses of natural products with promising pharmacological activities, including cinchona alkaloids, indole alkaloids, loganin, biotin, statins, and vitamin D.

Dr. Uskokovic authored 219 publications and acquired over 200 US patents. As a result of his ingenuity, he was inducted into the New Jersey Inventors Hall of Fame in 1994. He was a member of the advisory or editorial boards of six professional journals; was a member of the American Chemical Society and the New York Academy of Sciences; and was Adjunct Professor at Rutgers University. A laboratory at the Brown University, School of Medicine, Women and Infants Hospital of Rhode Island, was dedicated in honor of his research mentorship.

Dr. Uskokovic made major contributions to the vitamin D scientific community by establishing and perfecting the syntheses of vitamin D metabolites and multiple analogs. He generously provided and donated research samples of the numerous vitamin D analogs and intermediates that were synthesized in his laboratory. Prior to its commercial availability, Dr. Uskokovic provided $1,25(\text{OH})_2\text{D}_3$, at no cost, to any researcher who asked. In addition, he established strong collaborations with vitamin D scientists at Roche as well as around the world that included, among many others, Anthony W. Norman at University of

California Riverside, CA, Phillip Koeffler at University of California, Los Angeles, CA, David Feldman at Stanford University, CA, Michael Sporn at National Cancer Institute, NIH, MD, Sara Peleg at MD Anderson Cancer Center, TX, Michael F. Holick at Boston University, MA, Satyanarayana G. Reddy at Brown University, RI, George Studzinski, Sylvia Christakos, Allan Conney, and Nanjoo Suh at Rutgers University, NJ, John White at McGill University, Canada, Heide Cross at Vienna Medical School, Austria, Carsten Carlberg at the University of Eastern Finland, Finland, T. Okano at Kobe University, Japan, Luciano Adorini at BioXcell, Milan, Italy, and Dino Moras and Natacha Rochel, at IGBMC, France.

After his retirement from Roche in 1998, Dr. Uskokovic was instrumental in the support of Bioxell S.p.A., a new pharmaceutical company that emerged from Roche Milano. The medicinal chemistry branch, Bioxell Inc., was installed at Roche Nutley and Dr. Uskokovic headed that division until March 2010. A lead compound, Elocalcitol, a vitamin D analog with reduced calcemic activity, is in clinical trials for treatment of benign prostatic hyperplasia and overactive bladder. BXL746, another vitamin D analog, is in clinical trials for prevention of postsurgical adhesions. Dr. Uskokovic was instrumental in the discovery and development of these analogs.

Recent collaborative publications include the use of Dr. Uskokovic's vitamin D analogs to induce antimicrobial peptides, to inhibit proinflammatory cytokines from the respiratory epithelium in cystic fibrosis, to induce antileukemic activity, and to inhibit mammary carcinogenesis. In some recent studies, various analogs were shown to have activity to reduce tumor-initiating stem cell-like cell populations active in breast cancer development. His modification of structural elements in the vitamin D molecule allowed him to develop analogs that resisted degradation and therefore exhibited increased and prolonged activity. In other approaches to investigate the ligand-vitamin D receptor (VDR) interaction, Dr. Uskokovic designed the Gemini analogs with two side chains. These molecules exhibited high biological activity and reduced calcemic activity and were helpful in exploring the ligand-binding pocket of the VDR as well as many other functional activities.

Dr. Uskokovic had endless curiosity. Research in vitamin D was his passion. He was always enthusiastic about discussing experiments related to the use of vitamin D analogs (particularly if those experiments had possible clinical application) and he was always generous in providing vitamin D metabolites and analogs. He often quoted his fellow New Jersey inventor, Thomas Edison "I never did a day's work in my life. It was all fun". He is survived by his daughters Moira Bogrov, MD and Lila Vidger, PhD, their husbands and five grandchildren. Dr. Milan Uskokovic will be remembered worldwide for his long-lasting contributions to natural product chemistry and especially for his contributions to the vitamin D field that enabled many of the discoveries related to the multiple functions of vitamin D. He will be sorely missed by the entire vitamin D community.

Sylvia Christakos
Hubert Maehr
Nanjoo Suh
Rutgers University, New Jersey

Preface to the Fourth Edition

This new fourth edition of *Vitamin D* was written approximately 5–6 years after the third edition was published in 2011. At that time the exuberant hype about vitamin D as a “cure-all” for many diseases was close to its peak. In the ensuing years the hyperbole has not appeared to continue to escalate but has also not declined substantially. Numerous studies have been published in the intervening years, but many questions remain. The clinical and population studies, many well done, continue to alternate between positive data for benefit to extraskeletal sites and findings that show no value of elevated concentrations of 25(OH)D. Some naysayers have become strident in their conviction that vitamin D benefit is overblown, even for bone. Others remain strongly supportive of the value of vitamin D based on the compelling benefits of vitamin D, which have been demonstrated over and over again in cell cultures, animal models, and other preclinical studies. The population studies are also mixed, some showing positive findings for benefit while others are negative. However, there is a growing consensus that is clearly supportive of the view that vitamin D deficiency should be avoided. Everyone hopes that the randomized controlled trials (RCTs) ongoing in multiple parts of the world will eventually provide clear-cut answers. According to the NIH clinical trial register, there are numerous ongoing RCTs with an end point foreseen in the next 5 years so that we can expect a much broader insight into the clinical implications of vitamin D status. What to advise physicians and the public while we wait for answers that we hope will be coming, however, remains controversial.

In the intervening years between the third and fourth editions, we have seen the Institute of Medicine (IOM) committee report their recommendation for daily requirement of vitamin D to avoid deficiency and their view of the optimal target for circulating concentration of 25(OH)D needed for normal bones. They designate the 25(OH)D concentration of 20 ng/mL (50 nM/L) as the cut point for adequacy and their view that 600 IU per day for most adults and 800 IU for the elderly is sufficient for normal bones. Because extraskeletal benefits have not yet been proven by RCTs, their findings were based on their view of the data showing the vitamin D requirement for normal bones. The Endocrine Society took the issue with some of these findings, and their committee concluded that 30 ng/mL (75 nM/L) of 25(OH)D was required for optimum benefits to bone and suggested that this would require 1500–2000 IU/day to achieve. With the higher cut point for adequacy, the Endocrine Society position, consequently, is that vitamin D deficiency is far more common than that would be concluded from the IOM position, and it therefore would require higher daily intakes to achieve adequate levels of circulating vitamin D for the population. This controversy is highlighted in a new chapter in this edition where well-regarded proponents of

each position lay out their arguments and supportive data. We hope the reader will be better informed after reading both the positions.

In the new edition the editors have continued to constantly renew and remodel the book with each successive edition. To this end, David Feldman continues as editor-in-chief and Wes Pike as associate editor, but we have added four new editors with broad expertise to the team. John Adams has stepped down from the editor position, and we thank him for his excellent work on the third edition. As new editors, the undersigned hope to add fresh energy and expertise and expand the skill set of the editorial team to better cover the vast areas of science, health, and disease that is required for a book of this size and breadth.

The fourth edition has 117 chapters making the book somewhat larger than the third edition. The editors have worked very hard to revise and update this edition with new material and presentation of fresh and different perspectives from respected authors. Some chapters covered in the third edition have not been continued because relatively little new research was added in those areas. We thank the authors who are no longer contributing to this edition, for their previous efforts. They may well be asked to write in the next edition as we continue our strategy of rotating authors. All chapters have been revised and updated and many new references added. In our revitalization of the material in the book, we have added 40 new chapters to cover or expand into previously uncovered areas of research or to approach the subject from a different perspective. In addition, we have changed the senior authorship of 20 additional chapters that are now written by different authors who have been charged with revising and updating previous chapters. These extensive modifications to over half of the chapters in the book, with major updates and expansion of all of the chapters, has resulted in a substantially new, modified, and modernized book compared with the third edition. Finally, the expanded Internet availability of the text and the figures will make access to the material easier and more flexible and the addition of color figures alongside the text should enhance the illustrations and make the displayed data easier to understand.

Some of the areas given new emphasis in this edition include the evolution of vitamin D as a hormone; population studies and their methods of analysis; nutrition, fortification, and worldwide vitamin D deficiency; novel and improved techniques for vitamin D metabolite measurement and dealing with assay problems; new and expanded insights into the mechanism of vitamin D action; updates on vitamin D analogs and their progress in therapeutics; expanded coverage of vitamin D actions in cancer, inflammation and the immune system, diabetes, and other diseases; newly recognized target

tissues; exploration of additional organs and diseases that may be affected by vitamin D; and new biological pathways that regulate or are regulated by vitamin D. As we more fully appreciate the varied scope of vitamin D actions, it has become clearer that the vitamin D endocrine system affects most if not all tissues in the body. In fact, it is now apparent that there are likely two vitamin D systems. First, the well-established, tightly regulated systemic/endocrine system whereby renal synthesis of 1,25(OH)₂D adjusts serum calcium concentrations and regulates bone homeostasis. However, data are accumulating for a second parallel, widespread autocrine/paracrine system that can synthesize 1,25(OH)₂D locally under separate control mechanisms determined by assorted local factors. The full physiological impact of this paracrine system on extraskeletal sites remains to be fully validated, but the system appears to have disease- and tissue-specificity regulating various functions unrelated to calcium homeostasis. We have attempted to keep up with all of these advances by increasing our coverage of these newly recognized areas. We have enlisted the leading investigators in each area to provide truly expert opinion about each field.

An innovation in this edition is that we have chosen to commemorate two giants in our field who have recently passed away. We felt that Milan Uskokovich and Robert Heaney are clearly deserving of being honored and remembered in this way for their countless contributions over many years to the field of vitamin D. We cannot attempt to cover the passing of every deserving contributor to the field, and hopefully, this can be accomplished in annual meetings or other venues that occur yearly rather than in our book that is published much less frequently. However, we are very sad to announce that two additional eminent members of the vitamin D community died recently just as our book was going to press, and we are able to add a short paragraph about each of them to recognize their passing and their contributions to the field of vitamin D.

Adele Boskey passed away in May 2017. She was a pioneer in the field of bone mineralization using biophysical and imaging technologies to define the composition, structure, and functional properties of bone of normal subjects or in cases of major bone diseases such as osteoporosis, osteogenesis imperfecta, and rickets. She worked extensively on the nature of fractures and fracture healing, as well as many aspects of bone physiology and pathology. Adele was based

in the Hospital for Special Surgery, New York, where she also contributed much to the field of orthopedics and dentistry, as well as endocrinology. A full description of her outstanding career and many contributions can be found in *JBMR* 32:1597,2017.

Jeffrey O’Riordan who died in October 2017 was a leading figure in vitamin D research during the 1980s and 1990s. Based at the Middlesex Hospital in London, Jeffrey was a multidisciplinary mineral metabolism endocrinologist who played a pivotal role in developing novel areas of vitamin D research, including sarcoidosis and extrarenal 1 α -hydroxylase, oncogenic osteomalacia, and hereditary vitamin D-resistant rickets. Jeffrey was a prominent member of the international vitamin D community from the early days of its development, and the many successful trainees to come out of the O’Riordan Group in London included other notable vitamin D researchers including Larry Fraher, Tom Clemens, and Martin Hewison. A synopsis of Jeffrey’s career achievements and contributions to the field of vitamin D and mineral metabolism research can be found in *Journal of Endocrinology* 154:S1-2, 1997.

We want to extend our thanks and appreciation to the many authors who contributed to this volume. Without their hard work there, of course, would be no new edition. We therefore wish to express our gratitude for their willingness to offer their time and knowledge to make this book a success. We would like to thank the excellent team at Elsevier/Academic Press for their outstanding support of our efforts to produce this new edition. We especially thank Tari Broderick, Lisa Eppich, and Jeff Rossetti for their indispensable contributions to make this edition possible. Finally, we hope that this book will provide for our readers the authoritative information they seek about the significance and importance of vitamin D actions and will serve as the means to keep their knowledge current about the continuing growth of the field of vitamin D biology and its potential effects on health and disease.

David Feldman
Wes Pike
Roger Bouillon
Ed Giovannucci
David Goltzman
Martin Hewison

Abbreviations

1α-(OH)D₃ 1 α -Hydroxyvitamin D ₃	CDK or Cdk Cyclin-dependent kinase
1,25(OH)₂D₃ 1 α ,25-Dihydroxyvitamin D ₃	cDNA Complementary DNA
24,25(OH)₂D₃ 24,25-Dihydroxyvitamin D ₃	CDP Collagenase-digestible protein
25(OH)D₃ 25-Hydroxyvitamin D ₃	Cdx-2 Caudal-related homeodomain protein
5-ASA 5-Aminosalicylic acid	CFU Colony-forming unit
7-DHC 7-Dehydrocholesterol	cGMP Cyclic GMP
9-<i>cis</i>-RA 9- <i>cis</i> -retinoic acid	CGRP Calcitonin gene-related peptide
AA Arachidonic acid	CHF Congestive heart failure
AC Adenylyl cyclase	CK-II Casein kinase-II
ACE Angiotensin-converting enzyme	CLIA Competitive chemiluminescence immunoassay
ACF Activation frequency	cM Centimorgans
ACTH Adrenocorticotropin	Cm. Ln. Cement line
ADH Antidiuretic hormone (vasopressin)	CNS Central nervous system
ADHR Autosomal dominant hypophosphatemic rickets	CPBA Competitive protein-binding assay
ADP Adenosine diphosphate	cpm Counts per minute
AHO Albright's hereditary osteodystrophy	CRE cAMP response element
AI Adequate intake	CREB cAMP response element binding protein
AIDS Acquired immunodeficiency syndrome	CRF Chronic renal failure
Aj.AR Adjusted apposition rate	CsA Cyclosporin A
ALP Alkaline phosphatase	CSF Colony-stimulating factor
ANG II Angiotensin II	CT Calcitonin or computerized tomography
ANP Atrial natriuretic peptide	CTR Calcitonin receptor
APC Antigen-presenting cell	CTX Cerebrotendinous xanthomatosis
APD Aminohydroxypropylidene bisphosphonate	CVC Calcifying vascular cell
APL Atrichia with papular lesions	CYP Cytochrome P450
AR Androgen receptor	CYP24 Cytochrome P450, 24-hydroxylase
ARC Activator-recruited cofactor	DAG Diacylglycerol
ATP Adenosine triphosphate	DBD DNA-binding domain
ATRA All- <i>trans</i> -retinoic acid	DBP Diastolic blood pressure
AUC Area under the curve	DBP Vitamin-D-binding protein
B_{max} Maximum number of binding sites	DC Dendritic cell
BARE Bile acid response element	DCA Deoxycholic acid
bFGF Basic fibroblast growth factor	DCT Distal convoluted tubule
BFU Burst-forming unit	DEXA or DXA Dual energy X-ray absorptiometry
BGP Bone Gla protein (osteocalcin)	DHEA Dehydroepiandrosterone
BLM Basal lateral membrane	DHT Dihydrotestosterone or dihydrotestosterone
BMC Bone mineral content	DIC Disseminated intravascular coagulation
BMD Bone mineral density	DMSO Dimethyl sulfoxide
BMI Body mass index	DR Direct repeat
BMP Bone morphogenetic protein	DRIP Vitamin D receptor interacting protein
BMU Basic multicellular unit	DSP Dental sialoprotein
bp Base pairs	DSS Dextran sodium sulfate
BPH Benign prostatic hyperplasia	E₁ Estrone
BSA Bovine serum albumin	E₂ Estradiol
BUA Bone ultrasound attenuation	EAE Experimental autoimmune encephalitis
[Ca²⁺]_i Internal calcium ion molar concentration	EBT Electron beam computed technology
CaBP Calcium-binding protein	EBV Epstein-Barr virus
CAD Coronary artery disease	EC Endothelial cells
CaM Calmodulin	EC₅₀ or ED₅₀ Effective concentration (dose) to cause 50% effect
cAMP Cyclic AMP	ECaC Epithelium calcium channel
CaSR or CaR Calcium-sensing receptor	ECF Extracellular fluid
CAT Chloramphenicol acetyltransferase	EDTA Ethylenediaminetetraacetic acid
CBG Corticosteroid-binding globulin	EGF Epidermal growth factor
CBP Competitive protein-binding assay	ELISA Enzyme-linked immunosorbent assay
CC Chief complaint	EMSA Electrophoretic mobility shift assay
CD Crohn's disease	EP₁ PG receptor-1
CDCA Chenodeoxycholic acid	ER Estrogen receptor or endoplasmic reticulum

ERE Estrogen response element	IMCaI Intestinal membrane calcium-binding complex
ERK Extracellular signal-regulated kinase	iNKT Invariant NKT
Et Endothelin	i.p. Intraperitoneal
FACS Fluorescence-activated cell sorting or sorter	IP₃ Inositol trisphosphate
FAD Flavin adenine dinucleotide	IRMA Immunoradiometric assay
FCS Fetal calf serum	IU International units
FDA US Food and Drug Administration	IUPAC International Union of Pure and Applied Chemists
FFA Free fatty acid	i.v. Intravenous
FIT Fracture Intervention Trial	JG Juxtaglomerular
FMTC Familial medullary thyroid carcinoma	JNK c-Jun NH ₂ -terminal kinase
FP Formation period	K_d Dissociation constant
FRAP Fluorescence recovery after photobleaching	K_m Michaelis constant
FS Fanconi syndrome	kb Kilobases
FSK Forskolin	kbp Kilobase pairs
FXR Farnesoid X receptor	kDa Kilodaltons
g Gram	KO knockout
g Acceleration due to gravity	LBD Ligand-binding domain
G₀, G₁, G₂ Gap phases of the cell cycle	LCA Lithocholic acid
GAG Glycosaminoglycan	LDL Low-density lipoprotein
GC-MS Gas chromatography–mass spectrometry	Li. Ce. Lining cell
G-CSF Granulocyte colony-stimulating factor	LIF Leukemia inhibitory factor
GDNF Glial-cell-derived neurotrophic factor	LNH Late neonatal hypocalcemia
GFP Green fluorescent protein	LOD Logarithm of the odds
GFR Glomerular filtration rate	LPS Lipopolysaccharide
GH Growth hormone	LT Leukotriene
GHRH Growth-hormone-releasing hormone	LXR Liver X receptor
GIO Glucocorticoid-induced osteoporosis	M Mitosis phase of cell cycle
GM-CSF Granulocyte-macrophage colony-stimulating factor	M molar
GnRH Gonadotropin-releasing hormone	MAPK Mitogen-activated protein kinase
GR Glucocorticoid receptor	Mab Monoclonal antibody
GRE Glucocorticoid response element	MAR Matrix attachment region
GRTH Generalized resistance to thyroid hormone	MAR Mineral apposition rate
GWAS Genome-wide association study	MARRS Membrane-associated rapid response steroid
HAT Histone acetyltransferase	MCR Metabolic clearance rate
HDAC Histone deacetylase	M-CSF Macrophage colony-stimulating factor
HEK Human embryonic kidney	MEN2 Multiple endocrine neoplasia type 2
HHRH Hereditary hypophosphatemic rickets with hypercalciuria	MGP Matrix Gla protein
HIV Human immunodeficiency virus	MHC Major histocompatibility complex
HNF Hepatocyte nuclear factor	min Minute
HPI History of present illness	MIU Million international units
HPLC High-performance liquid chromatography	MLR Mixed lymphocyte reaction
HPV Human papilloma virus	Mlt Mineralization lag time
h Hour	MR Mineralocorticoid receptor
HR <i>Hairless</i>	MRI Magnetic resonance imaging
HRE Hormone response element	mRNA Messenger ribonucleic acid
HSA Human serum albumin	MS Multiple sclerosis
Hsp Heat-shock protein	MT Metric ton
HSV Herpes simplex virus	MTC Medullary thyroid carcinoma
HVDRR Hereditary vitamin-D-resistant rickets	NADH Nicotinamide adenine dinucleotide
HVO Hypovitaminosis D osteopathy	NADPH Nicotinamide adenine dinucleotide phosphate
IBD Inflammatory bowel disease	NAF Nuclear accessory factor
IBMX Isobutylmethylxanthine	NBT Nitroblue tetrazolium
IC₅₀ Concentration to inhibit 50% effect	NcAMP Nephrogenous cAMP
ICA Intestinal calcium absorption	NCP Noncollagen protein
ICMA Immunochemiluminometric assay	NFκB Nuclear factor kappa B
IDBP Intracellular vitamin-D-binding protein	NGF Nerve growth factor
IDDM Insulin-dependent diabetes mellitus	NHANES III National Health and Nutrition Examination Survey III
IDM Infants of diabetic mothers	NHL Non-Hodgkin's lymphoma
IEL Intraepithelial cells	NIDDM Non-insulin-dependent diabetes mellitus
IFN Interferon	NIH National Institutes of Health
Ig Immunoglobulin	NK cell Natural killer cell
IGFBP IGF-binding protein	NLS Nuclear localization signal
IGF-I, -II Insulin-like growth factor type I, II	NMR Nuclear magnetic resonance
IGF-IR IGF-I receptor	NOD Nod-like
IL Interleukin (e.g., IL-1, IL-1β, etc.)	NPT Sodium/phosphate cotransporter
i.m. Intramuscular	NR Nuclear receptor

Ob	Osteoblast	RDA	Recommended dietary allowance
Oc	Osteocalcin or osteoclast	RFLP	Restriction fragment length polymorphism
OCIF	Osteoclastogenesis inhibitory factor (same as OPG)	RIA	Radioimmunoassay
OCT	22-Oxacalcitriol	RID	Receptor interacting domain
ODF	Osteoclast differentiation factor (same as RANKL)	RNase	Ribonuclease
OHO	Oncogenic hypophosphatemic osteomalacia	ROCs	Receptor-operated calcium channels
Omt	Osteoid maturation time	ROS	Reactive oxygen species
OPG	Osteoprotegerin	RPA	Ribonuclease protection assay
OPN	Osteopontin	RRA	Radioreceptor assay
OSM	Oncostatin M	RT-PCR	Reverse transcriptase-polymerase chain reaction
OVX	Ovariectomy	RXR	Retinoid X receptor
P_i	Inorganic phosphate	RXRE	Retinoid X receptor response element
PA₂	Phospholipase A ₂	SBP	Systolic blood pressure
PAD	Peripheral arterial vascular disease	SD	Standard deviation
PAM	Pulmonary alveolar macrophage	SDS	Sodium dodecyl sulfate
PBL	Peripheral blood lymphocyte	SE	Standard error
PBMC	Peripheral blood mononuclear cells	SEM	Standard error of the mean
PBS	Phosphate-buffered saline	SH	Social history
PC	Phosphatidylcholine	SHBG	Sex-hormone-binding globulin
PCNA	Proliferating cell nuclear antigen	SLE	Systemic lupus erythematosus
PCR	Polymerase chain reaction	SNP	Single nucleotide polymorphism
PCT	Proximal convoluted tubule	SOS	Speed of sound
PDDR	Pseudovitamin D deficiency rickets	Sp1	Selective promoter factor 1
PDGF	Platelet-derived growth factor	SPF	Sun protection factor
PEIT	Percutaneous ethanol injection therapy	SRC-1	Steroid receptor coactivator-1
PHEX	Phosphate-regulating gene with homologies to endopeptidases on the X chromosome	SSCP	Single-strand conformational polymorphism
PG	Prostaglandin	SV40	Simian virus 40
PHA	Phytohemagglutinin	SXA	Single energy X-ray absorptiometry
PHP	Pseudohypoparathyroidism	t_{1/2}	Half-time
PIC	Preinitiation complex	T₃	Triiodothyronine
PKA	Protein kinase A	T₄	Thyroxine
PKC	Protein kinase C	TBG	Thyroid-binding globulin
PKI	Protein kinase inhibitor	TBP	TATA-binding protein
PLA₂	Phospholipase A ₂	TC	Tumoral calcinosis
PLC	Phospholipase C	TF	Tubular fluid
PMA	Phorbol 12-myristate 13-acetate	TFIIB	General transcription factor IIB
PMCA	Plasma membrane calcium pump	TG	Transgenic
PMH	Past medical history	TGF	Transforming growth factor
p.o.	Oral	TIO	Tumor-induced osteomalacia
poly(A)	Polyadenosine	TK	Thymidine kinase
PPAR	Peroxisome proliferator-activated receptor	TLR	Toll-like receptor
PR	Progesterone receptor	TmP or TmPi	Tubular absorptive maximum for phosphorus
PRA	Plasma renin activity	TNBS	Trinitrobenzene sulfonic acid
PRL	Prolactin	TNF	Tumor necrosis factor
PRR	Pattern recognition receptors	TPA	12-O-tetradecanoylphorbol-13-acetate
PSA	Prostate-specific antigen	TPN	Total parenteral nutrition
PSI	Psoriasis severity index	TPTX	Thyroparathyroidectomized
PT	Parathyroid	TR	Thyroid hormone receptor
PTH	Parathyroid hormone	TRAP	Tartrate-resistant acid phosphatase
PTHrP	Parathyroid hormone-related peptide	TRAP	Thyroid hormone receptor-associated proteins
PTX	Parathyroidectomy	TRP	Transient receptor potential
PUVA	Psoralen-ultraviolet A	TRE	Thyroid hormone response element
QCT	Quantitative computerized tomography	TRE	TPA response element
QSAR	Quantitative structure-activity relationship	TRH	Thyrotropin-releasing hormone
RA	Retinoic acid	Trk	Tyrosine kinase
RA	Rheumatoid arthritis	TSH	Thyrotropin
Rag	Recombination-activating gene	TSS	Transcription start site
RANK	Receptor activator NF-κB	UF	Ultrafiltrable fluid
RANKL	Receptor activator NF-κB ligand	US	Ultrasonography
RAP	Receptor-associated protein	USDA	US Department of Agriculture
RAR	Retinoic acid receptor	UTR	Untranslated region
RARE	Retinoic acid response element	UV	Ultraviolet
RAS	Rennin-angiotensin system	VDDR-I	Vitamin-D-dependent rickets type I (<i>see</i> PDDR)
RBP	Retinol-binding protein	VDDR-II	Vitamin-D-dependent rickets type II (<i>see</i> HVDRR)
RCI	Relative competitive index	VDR	Vitamin D receptor
		VDRE	Vitamin D response element

ABBREVIATIONS

VDRL Vitamin D receptor ligand	WRE Wilms' tumor gene, WT1, responsive element
VEGF Vascular endothelial growth factor	WSTF Williams syndrome transcription factor
VERT Vertebral Efficacy with Risedronate Therapy studies	WT Wild-type
VICCs Voltage-insensitive calcium channels	XLH X-linked hypophosphatemic rickets
VSMC Vascular smooth muscle cell	XRD X-ray diffraction
VSSCs Voltage-sensitive calcium channels	ZEB Zinc finger, E box-binding transcription factor
WHI Women's Health Initiative	

Relevant Lab Values in Adults and Children

CRITERIA FOR VITAMIN D DEFICIENCY: 25(OH)D SERUM LEVELS

Recommendations for Adults

Institute of Medicine recommendations		
	Conventional Units (ng/mL)	SI Units (nmol/L)
Deficient	<20	<50
Normal	≥20	≥50
Excessive	>50	>125

Frequently used vitamin D cut points by many laboratories similar to the Endocrine Society guidelines

	Conventional Units (ng/mL)	SI Units (nmol/L)
Deficient	<20	<50
Insufficient	20–29.9	50–74.9
Sufficient	30	>75

Recommendations for pediatrics

nmol/L	ng/mL	Journal of Clinical Endocrinology and Metabolism ^a	Nature Rev Endo ^b
>50	20	Sufficiency	Sufficiency
30–50	12–20	Insufficiency	Deficiency
<30	12	Deficiency	Severe deficiency

^aMunns CF, et al. Global consensus recommendations on prevention and management of nutritional rickets. *J Clin Endocrinol Metab* 2016;101:394–415.

^bBouillon R. *Nat Rev Endocrinol* August 2017;13(8):466–79.

Approximate normal ranges for serum values in adults^a

Measure	Conventional Units	SI Units	Conversion Factor ^b
Ionized calcium	4.5–5.3 mg/dL	1.12–1.32 mmol/L	0.2495
Total calcium	8.7–10.1 mg/dL	2.17–2.52 mmol/L	0.2495
Phosphorous, inorganic	2.4–4.6 mg/dL	0.77–1.49 mol/L	0.3229
1,25(OH) ₂ D	25–45 pg/mL	60–108 pmol/L	2.40

^aNormal ranges differ in various laboratories and these values are provided only as a general guide.

^bConversion factor X conventional units = SI units.

Approximate normal ranges for serum values in children^a

Measure	Conventional Units	SI Units	Conversion Factor ^b
Ionized calcium	4.8–5.2 mg/dL	1.19–1.29 mmol/L	0.2495
Total calcium	9.0–10.5 mg/dL	2.25–2.63 mmol/L	0.2495
Phosphorous, inorganic	3.8–5.0 mg/dL	1.23–1.62 mol/L	0.3229
1,25(OH) ₂ D	27–56 pg/mL	65–134 pmol/L	2.40

^aNormal ranges differ in various laboratories and these values are provided only as a general guide.

^bConversion factor X conventional units = SI units.

Useful equivalencies of different units

Vitamin D	1 µg = 40 IU
Calcium	1 mmol = 40 mg
Phosphorus	1 mmol = 30 mg

This page intentionally left blank

S E C T I O N I

HISTORY, CHEMISTRY METABOLISM,
CIRCULATION & REGULATION

This page intentionally left blank

Historical Overview of Vitamin D

Hector F. DeLuca

University of WI-Madison, Madison, WI, United States

OUTLINE

Discovery of the Vitamins	3	Discovery of the Hormonal Form of Vitamin D	6
<i>Early Nutritional Views</i>	3	<i>Early Work of Kodicek</i>	6
<i>McCollum and Osborne and Mendel's Discovery of Vitamin A and B Complex</i>	4	<i>Radiolabeled Vitamin D Experiments</i>	6
<i>History of Rickets</i>	4	<i>Isolation and Identification of the Active Form of Vitamin D</i>	7
<i>Discovery of Vitamin D</i>	4	<i>Proof That 1,25(OH)₂D₃ Is the Active Form of Vitamin D</i>	7
<i>Discovery That Vitamin D Is Not a Vitamin</i>	4	<i>Discovery of the Vitamin D Endocrine System</i>	7
<i>Isolation and Identification of Nutritional Forms of Vitamin D</i>	5	<i>Other Metabolites of Vitamin D</i>	8
Discovery of the Physiological Functions of Vitamin D	5	<i>Discovery of the Vitamin D Receptor</i>	8
<i>Intestinal Calcium and Phosphorus Absorption</i>	5	Acknowledgment	9
<i>Mobilization of Calcium From Bone</i>	5	References	9
<i>Renal Reabsorption of Calcium and Phosphorus</i>	6		
<i>Discovery of New Functions of Vitamin D</i>	6		

DISCOVERY OF THE VITAMINS

Early Nutritional Views

The field of nutrition was largely dominated in the 19th century by German chemists, led by Justus von Liebig [1]. They taught that adequacy of the diet could be described by an analysis of protein, carbohydrate, fat, and mineral. Thus, a diet containing 12% protein, 5% mineral, 10%–30% fat, and the remainder as carbohydrate would be expected to support normal growth and reproduction. This view remained largely unchallenged until the very end of the 19th century and the beginning of the 20th century [2–5]. However, evidence opposing this view began to appear. One of the first was the famous study of Eijkman who studied prisoners in the Dutch East Indies maintained on a diet of polished rice [6]. A high incidence of the neurological disorder beriberi was recorded in these inmates. Eijkman found that either feeding whole rice or returning the hulls of the polished rice could eliminate beriberi.

Eijkman reasoned that polished rice contained a toxin that was somehow neutralized by the rice hulls. Later, a colleague, Grijns [7], revisited the question and correctly demonstrated that hulls contained an important and required nutrient that prevented beriberi.

Other reports revealed that microorganic nutrients might be present. The development of scurvy in mariners was a common problem. This disease was prevented by the consumption of limes on British ships (hence, the term “Limey” to describe British sailors) and sauerkraut and fruits on other ships. This led Holst and Frohlich to conclude that scurvy could be prevented by a nutrient present in these foods [8]. Experiments by Lunin, Magendie, Hopkins, and Funk showed that a diet of purified carbohydrate, protein, fat, and salt is unable to support growth and life of experimental animals [2–5]. This suggested that some unknown or vital factor present in natural foods was missing from the purified diets. Hopkins developed a growth test in which natural foods were found to support rapid growth of experimental animals, whereas purified

materials could not [3]. Funk had found similar results for the prevention of neuritis and reasoned that there were “vital amines” present in foods from natural sources and actually provided the basis for the term “vitamins” used later to describe essential micronutrients [5].

McCollum and Osborne and Mendel’s Discovery of Vitamin A and B Complex

A key experiment demonstrating essential micronutrients was one carried out at the Wisconsin Agricultural Experiment Station, engineered by Stephen Moulton Babcock and carried out by E. B. Hart supported by McCollum and Steenbock [9]. Herds of dairy cows were maintained on a diet composed individually only of corn, oats, or wheat or were fed a mixture of all of these grains, all receiving the same amount of carbohydrate, protein, fat, and salts and all providing equal analysis according to the German chemists [1]. The animals on the corn diet did very well, produced milk in large amounts, and reproduced normally. Those on the wheat diet failed to thrive and soon were unable to reproduce or lactate. The oat group was found to be intermediate between the corn and wheat groups, and the mixture approximated the growth and reproduction found with corn. Yet all these diets had the same proximate analysis.

The conclusion of the Wisconsin Experiment Station study was that there are unknown nutrients present in corn and not found in wheat that are essential for life and reproduction. This led E. B. Hart, Chairman of Agricultural Chemistry (now Biochemistry) at Wisconsin, to conceive that a search for these nutrients must begin. Professor Hart assigned this task to Professor Elmer McCollum. Professor McCollum decided to search for these nutrients using small experimental animals to minimize the cost and labor associated with large animals used in the single-grain experiments. McCollum and Davis demonstrated in rats there was present in butter fat a substance that prevented xerophthalmia and was also required for growth. They termed this “a lipid-soluble growth factor” [10]. McCollum later named this factor “vitamin A” [11]. This substance was absent from lard and other fats but was found in large amounts in cod liver oil. In constructing the diets, McCollum obtained the carbohydrates and salts from milk whey that, unknown to him, supplied the vitamin B complex group of micronutrients that permitted him to observe a vitamin A deficiency. McCollum at Wisconsin [11] and Osborne and Mendel [12] at the Connecticut Experiment Station carried out experiments in which cod liver oil was used as a source of fat in the diet, but the minerals were supplied from pure chemicals mixed to approximate the mineral composition of milk. Starch or sugar was used as the carbohydrate. These animals developed a different group of symptoms, namely, neuritis, which could be cured by the provision of the milk components. McCollum and Osborne and Mendel correctly concluded that this activity was because of a different micronutrient called “vitamin B.” These experiments ushered in the concept of the organic micronutrients known as vitamins.

History of Rickets

The disease rickets was very likely known in antiquity but was described in the 15th century as revealed by later writings. Whistler first provided a clear description of rickets in which the skeleton was poorly mineralized and deformed [13]. Rickets undoubtedly in ancient times appeared only on rare occasions and hence was not considered a problem. However, at the end of the 19th century, the Industrial Revolution had taken place: a highly agrarian population had become urbanized, and smoke from the industrial plants polluted the atmosphere. Thus, in low-sunlight countries such as England, rickets appeared in epidemic proportions. In fact, it was known as the English Disease [14]. Some reports of the beneficial action of cod liver oil had appeared. However, they were not given scientific credence.

With the discovery of the vitamins, Sir Edward Mellanby in Great Britain began to reason that rickets might also be a disease caused by a dietary deficiency [15]. Mellanby fed dogs a diet composed primarily of oatmeal, which was the diet consumed where the incidence of rickets was the highest (i.e., Scotland). McCollum inadvertently maintained the dogs indoors and away from ultraviolet light. The dogs developed severe rickets. Learning from the experiments of McCollum, Mellanby provided cod liver oil to cure or prevent the disease. Mellanby could not decide whether the healing of rickets was because of vitamin A known to be present in the cod liver oil or whether it was a new and unknown substance. Therefore, the activity of healing rickets was first attributed to vitamin A.

Discovery of Vitamin D

McCollum, who had moved to Johns Hopkins from Wisconsin, continued his experiments on the fat-soluble materials. McCollum used aeration and heating of cod liver oil to destroy the vitamin A activity or the ability to support growth and prevent xerophthalmia [16]. However, cod liver oil treated in this manner still retained the ability to cure rickets. McCollum correctly reasoned that the activity in healing rickets was due to a new and heretofore unknown vitamin that became known as vitamin D. Vitamin C was assigned to the antiscorbutic substance [17]. On the basis of the experiments of McCollum and Mellanby, vitamin D became known as an essential nutrient.

Discovery That Vitamin D Is Not a Vitamin

At the same time Sir Edward Mellanby was carrying out the experiments in dogs, Huldshinsky [18] and Chick et al. [19] independently found that rickets in children could be prevented or cured by exposing them to sunlight or to artificially induced ultraviolet light. Thus, the curious findings were that sunlight and ultraviolet light somehow equaled cod liver oil. These strange and divergent results required resolution.

Steenbock and Hart had noted in 1916 the importance of sunlight in restoring positive calcium balance in goats [20]. At Wisconsin, with McCollum carrying out experiments in small

experimental animals (i.e., rats), Steenbock was required to work with larger animals. Steenbock then began to study goats because they would consume less material and could serve as better experimental animals than cows. Steenbock began to study the calcium balance of lactating goats and found that those goats maintained outdoors in the sunlight were found to be in positive calcium balance, whereas those maintained indoors lost a great deal of their skeletal calcium to lactation [20]. Steenbock and Hart, therefore, noted the importance of sunlight (or at least, outdoors) on calcium balance. This work then undoubtedly led Steenbock to realize that the ultraviolet healing properties described by Huldschinsky might be related to the calcium balance experiments in goats. By irradiating the animals and diets, Steenbock and Black found that vitamin D activity could be induced and rickets could be cured [21]. A similar finding was reported soon thereafter by Hess and Weinstock [22]. Steenbock then traced this to the nonsaponifiable fraction of the lipids in foods [23]. He found that ultraviolet light activated an inactive substance to become a vitamin D-active material. Thus, ultraviolet light could be used to irradiate foods, induce vitamin D activity, and fortify foods to eliminate rickets as a major medical problem. This discovery also made available a source of vitamin D for isolation and identification.

Isolation and Identification of Nutritional Forms of Vitamin D

From irradiation of mixtures of plant sterols, Windaus and colleagues isolated a material that was active in healing rickets [24]. This substance was called “vitamin D₁,” but its structure was not determined. Vitamin D₁ proved to be an adduct of tachysterol and vitamin D₂, and thus vitamin D₁ was actually an error in identification. The British group led by Askew was successful in isolating and determining the structure of the first vitamin D, vitamin D₂ or ergocalciferol, from irradiation of plant sterols [25]. A similar identification by the Windaus group confirmed the structure of vitamin D₂ [26]. Windaus and Bock also isolated the precursor of vitamin D₃ from skin, namely, 7-dehydrocholesterol [27]. Furthermore, 7-dehydrocholesterol was synthesized [28] and converted to vitamin D₃ (cholecalciferol) as identified by the Windaus group [29]. Thus, the structures of nutritional forms of vitamin D became known (Fig. 1.1). Windaus and Bock, having isolated 7-dehydrocholesterol from skin, provided the presumptive evidence that vitamin D₃ is the form of vitamin D produced in skin, a discovery that was later confirmed by the chemical identification of vitamin D₃ in skin by Esvelt et al. [30] and of a previtamin D₃ in skin by Holick et al. [31]. Synthetic vitamin D as produced by the irradiation process replaced the irradiation of foods as a means of fortifying foods with vitamin D and was also rapidly applied to rickets and tetany and in the provision to domestic animals such as chickens, cows, and pigs.

Windaus' group provided chemical syntheses of the vitamin D compounds, confirming their structures and thus ending the era of the isolation and identification of nutritional




FIGURE 1.1 Nutritional forms of vitamin D.

forms of vitamin D and making them available for the treatment of disease. Although Windaus received the 1928 Nobel Prize in chemistry, it was for his general work on steroids.

DISCOVERY OF THE PHYSIOLOGICAL FUNCTIONS OF VITAMIN D

Intestinal Calcium and Phosphorus Absorption

Besides bone mineralization, the earliest discovered function of vitamin D is its important role in the absorption and utilization of calcium. The first report of this finding was in the early 1920s by Orr and colleagues [32]. Kletzien et al. [33] demonstrated that vitamin D plays an important role in the utilization of calcium from the diet, and a number of experiments were carried out on the utilization of calcium and phosphorus from cereal diets. Nicolaysen was responsible, however, for demonstrating unequivocally the role of vitamin D in the absorption of calcium and independently of phosphorus from the diet [34]. Nicolaysen also followed the early work of Kletzien et al. [33] in which animals adapted to a low-calcium diet were better able to utilize calcium than animals on an adequate calcium diet. This work was confirmed by Nicolaysen, who postulated the existence of an “endogenous factor” that would inform the intestine of the skeletal needs for calcium [35]. This endogenous factor later proved to be largely the active form of vitamin D, 1,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃) [36]. Strong support for this concept was provided by the studies of Ribovitch et al. [37], which showed animals maintained on a constant exogenous source of 1,25(OH)₂D₃ are unable to change intestinal calcium transport in response to changes in dietary calcium levels. Chapter 20 will present a detailed review of the role of vitamin D in the regulation of intestinal calcium absorption.

Mobilization of Calcium From Bone

For many years, investigators have attempted to show that vitamin D plays a role directly on the mineralization process of the skeleton. However, early work by Howland

and Kramer [38], later work by Lamm and Neuman [39], and more recent work by Underwood and DeLuca [40] demonstrated very clearly that vitamin D does not play a significant role in the actual mineralization process of the skeleton but that the failure to mineralize the skeleton in vitamin D deficiency is due to inadequate levels of calcium and phosphorus in the plasma. Thus, the action of vitamin D in mineralizing the skeleton and in preventing hypocalcemic tetany is the elevation of plasma calcium and phosphorus [41]. These discoveries laid to rest the concept of a role of vitamin D in mineralization. However, Carlsson [42] and Bauer et al. [43] were the first to realize that a major function of vitamin D is to induce the mobilization of calcium from bone when required. Thus, in animals on a low-calcium diet, the rise in serum calcium induced by vitamin D is the result of actual mobilization of calcium from bone [44]. This important function is known to be essential for the provision of calcium to meet soft tissue needs, especially those of nerves and muscle, on a minute-to-minute basis when it is in insufficient supply from the diet. It is likely that the function of vitamin D in mobilizing calcium from bone is an osteoclastic-mediated process [45]. It is clear, however, that both vitamin D and parathyroid hormone are required for this function [46]. Furthermore, it is clear that vitamin D plays an important role in osteoclastic-mediated bone resorption [47], which is certainly the first and essential event in bone remodeling [48].

Renal Reabsorption of Calcium and Phosphorus

A significant site of vitamin D action to elevate plasma calcium is in the distal renal tubule. Although experiments were suggestive of a role for vitamin D in increasing renal tubule reabsorption of calcium, a clear demonstration of this did not occur until the late 1980s at the hands of Yamamoto et al. [49]. The renal tubule reabsorbs 99% of the filtered calcium even in the absence of vitamin D. However, reabsorption of the last 1% of the filtered load requires both vitamin D and parathyroid hormone. Thus, these agents work in concert in the renal reabsorption of calcium as well as in the mobilization of calcium from bone. Both agents are required to carry out this function. A review of the renal actions of vitamin D can be found in Chapters 26 and 79.

Discovery of New Functions of Vitamin D

With discovery of the receptor for the vitamin D hormone (described below) came the surprising result that this receptor could be found in a variety of tissues not previously appreciated as targets of vitamin D action. It localizes in the distal renal tubule cells, enterocytes of the small intestine, bone lining cells, osteoblasts, and osteoclasts in keeping with its known role in calcium metabolism [50,51]. However, its appearance in tissues such as parathyroid gland, islet cells of the pancreas, cells in bone marrow (i.e., promyelocytes), lymphocytes, and certain neural cells raised the question of whether the functions of vitamin D might be broader than

previously anticipated [50,51]. As a result of those findings, new functions of vitamin D have been found. For example, vitamin D plays a role in causing differentiation of promyelocytes to monocytes and the subsequent coalescing of the monocytes into multinuclear osteoclast precursors and ultimately into active osteoclasts [52,53]. The target of vitamin D in this function is the osteoblast and osteocyte. In response to the hormonal form of vitamin D (see below), RANK ligand is produced, which signals osteoclastogenesis and osteoclastic activation [52,53]. Suppression of parathyroid cell growth and suppression of parathyroid hormone gene expression represent other new vitamin D actions [54,55]. In keratinocytes of skin, vitamin D appears to play a role in suppression of growth and in cellular differentiation [56]. Likely, discoveries of many new functions of $1,25(\text{OH})_2\text{D}_3$ will be made and are well on their way, as described in the later chapters of this volume.

DISCOVERY OF THE HORMONAL FORM OF VITAMIN D

Early Work of Kodicek

The true pioneer of vitamin D metabolism was Egan Kodicek working at the Dunn Nutritional Laboratory in Cambridge. Kodicek used a bioassay at first to study the fate of the vitamin D molecule and found that much vitamin D was converted to biologically inactive products [57]. Clearly, however, this approach of assaying vitamin D activity following administration of known doses of vitamin D was of limited value in determining metabolism.

Radiolabeled Vitamin D Experiments

Professor Kodicek then began to synthesize radiolabeled vitamin D_2 . Unfortunately, the degree of labeling was not sufficient to permit the administration of truly physiological doses of vitamin D. Nevertheless, Professor Kodicek continued investigations into this important area. At the conclusion of 10 years of work, he concluded that vitamin D was active without metabolic modification and that the metabolites that were found were biologically inactive [58]. This conclusion was reached even as late as 1967, when it was concluded that vitamin D_3 itself was the active form of vitamin D in the intestine [59]. However, chemical synthesis of radiolabeled vitamin D_3 of high specific activity in the laboratory of the author proved to be of key importance in the demonstration of biologically active metabolites [60]. By providing a truly physiological dose of vitamin D, it could be learned that the vitamin D itself disappeared and instead polar metabolites could be found in the target tissues before those tissues responded [61]. The polar metabolites proved to be more biologically active and acted more rapidly than vitamin D itself [62]. Thus, presumptive evidence of conversion of vitamin D to active forms had been obtained as early as 1967.